<full-text-retrieval-response xmlns="http://www.elsevier.com/xml/svapi/article/dtd" xmlns:bk="http://www.elsevier.com/xml/bk/dtd" xmlns:cals="http://www.elsevier.com/xml/common/cals/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:ja="http://www.elsevier.com/xml/ja/dtd" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/dtd" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/dtd" xmlns:tb="http://www.elsevier.com/xml/common/table/dtd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xocs="http://www.elsevier.com/xml/xocs/dtd" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><coredata><prism:url>https://api.elsevier.com/content/article/pii/S1359644621002488</prism:url><dc:identifier>doi:10.1016/j.drudis.2021.05.016</dc:identifier><eid>1-s2.0-S1359644621002488</eid><prism:doi>10.1016/j.drudis.2021.05.016</prism:doi><pii>S1359-6446(21)00248-8</pii><dc:title>TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery </dc:title><prism:publicationName>Drug Discovery Today</prism:publicationname><prism:aggregationType>Journal</prism:aggregationtype><pubType>rev</pubtype><prism:issn>13596446</prism:issn><dc:format>text/xml</dc:format><prism:coverDate>2021-05-27</prism:coverdate><prism:coverDisplayDate>Available online 27 May 2021</prism:coverdisplaydate><prism:copyright>Â© 2021 Published by Elsevier Ltd.</prism:copyright><prism:publisher>Published by Elsevier Ltd.</prism:publisher><dc:creator>Xiang, Shuang</dc:creator><dc:creator>Song, Shukai</dc:creator><dc:creator>Tang, Haotian</dc:creator><dc:creator>Smaill, Jeff B.</dc:creator><dc:creator>Wang, Aiqun</dc:creator><dc:creator>Xie, Hua</dc:creator><dc:creator>Lu, Xiaoyun</dc:creator><dc:description>
                  Dysregulation of TANK-binding kinase 1 (TBK1) homeostasis leads to the occurrence and progression of many diseases, such as inflammation, autoimmune diseases, metabolic diseases, and cancer. Therefore, there is a need to develop TBK1 inhibitors as therapeutic agents. In this review, we highlight the diverse biological functions of TBK1 and summarize the promising small-molecule inhibitors of TBK1 that have the potential to be developed as therapeutic candidates.
               </dc:description><openaccess>0</openaccess><openaccessArticle>false</openaccessarticle><openaccessType/></openaccesstype><openArchiveArticle>false</openarchivearticle><openaccessSponsorName/></openaccesssponsorname><openaccessSponsorType/></openaccesssponsortype><openaccessUserLicense/></openaccessuserlicense><link href="https://api.elsevier.com/content/article/pii/S1359644621002488" rel="self"/></link><link href="https://www.sciencedirect.com/science/article/pii/S1359644621002488" rel="scidir"/></link></coredata><objects><object ref="ga1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="282" height="200" size="18635">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-ga1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="788" height="717" size="111861">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr1.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="752" height="437" size="65225">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr2.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="556" height="313" size="26565">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr3.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4a" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="706" height="397" size="49961">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr4a.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4b" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="689" height="385" size="36974">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr4b.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="576" height="409" size="64877">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr6.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="standard" type="IMAGE-DOWNSAMPLED" multimediatype="JPEG image file" mimetype="image/jpeg" width="622" height="381" size="60767">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr5.jpg?httpAccept=%2A%2F%2A</object><object ref="ga1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="155" size="11541">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-ga1.sml?httpAccept=%2A%2F%2A</object><object ref="gr1" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="180" height="164" size="10529">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr1.sml?httpAccept=%2A%2F%2A</object><object ref="gr2" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="127" size="8390">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr2.sml?httpAccept=%2A%2F%2A</object><object ref="gr3" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="123" size="5694">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr3.sml?httpAccept=%2A%2F%2A</object><object ref="gr4a" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="123" size="7700">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr4a.sml?httpAccept=%2A%2F%2A</object><object ref="gr4b" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="122" size="5685">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr4b.sml?httpAccept=%2A%2F%2A</object><object ref="gr6" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="156" size="13298">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr6.sml?httpAccept=%2A%2F%2A</object><object ref="gr5" category="thumbnail" type="IMAGE-THUMBNAIL" multimediatype="GIF image file" mimetype="image/gif" width="219" height="134" size="7216">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr5.sml?httpAccept=%2A%2F%2A</object><object ref="ga1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="1248" height="886" size="136071">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-ga1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr1" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3489" height="3176" size="757965">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr1_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr2" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3331" height="1936" size="471061">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr2_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr3" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2461" height="1384" size="188429">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr3_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4a" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3126" height="1760" size="379190">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr4a_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr4b" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="3051" height="1704" size="276137">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr4b_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr6" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2552" height="1814" size="430491">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr6_lrg.jpg?httpAccept=%2A%2F%2A</object><object ref="gr5" category="high" type="IMAGE-HIGH-RES" multimediatype="JPEG image file" mimetype="image/jpeg" width="2756" height="1688" size="409032">https://api.elsevier.com/content/object/eid/1-s2.0-S1359644621002488-gr5_lrg.jpg?httpAccept=%2A%2F%2A</object></objects><scopus-id>85107778755</scopus-id><scopus-eid>2-s2.0-85107778755</scopus-eid><pubmed-id>34051368</pubmed-id><link href="https://api.elsevier.com/content/abstract/scopus_id/85107778755" rel="abstract"/></link><originalText><xocs:doc xsi:schemaLocation="http://www.elsevier.com/xml/xocs/dtd http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd"><xocs:meta xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <xocs:content-family>serial</xocs:content-family>
      <xocs:content-type>JL</xocs:content-type>
      <xocs:cid>271275</xocs:cid>
      <xocs:ssids>
         <xocs:ssid type="alllist">291210</xocs:ssid>
         <xocs:ssid type="subj">291727</xocs:ssid>
         <xocs:ssid type="subj">291850</xocs:ssid>
         <xocs:ssid type="subj">291928</xocs:ssid>
         <xocs:ssid type="content">31</xocs:ssid>
      </xocs:ssids>
      <xocs:srctitle>Drug Discovery Today</xocs:srctitle>
      <xocs:normalized-srctitle>DRUGDISCOVERYTODAY</xocs:normalized-srctitle>
      <xocs:orig-load-date yyyymmdd="20210527">2021-05-27</xocs:orig-load-date>
      <xocs:available-online-date yyyymmdd="20210527">2021-05-27</xocs:available-online-date>
      <xocs:ew-transaction-id>2021-06-09T19:39:59</xocs:ew-transaction-id>
      <xocs:eid>1-s2.0-S1359644621002488</xocs:eid>
      <xocs:pii-formatted>S1359-6446(21)00248-8</xocs:pii-formatted>
      <xocs:pii-unformatted>S1359644621002488</xocs:pii-unformatted>
      <xocs:doi>10.1016/j.drudis.2021.05.016</xocs:doi>
      <xocs:item-stage>S200</xocs:item-stage>
      <xocs:item-version-number>S200.1</xocs:item-version-number>
      <xocs:item-weight>FULL-TEXT</xocs:item-weight>
      <xocs:timestamp yyyymmdd="20210610">2021-06-10T01:22:19.515103Z</xocs:timestamp>
      <xocs:dco>0</xocs:dco>
      <xocs:tomb>0</xocs:tomb>
      <xocs:date-search-begin>20210527</xocs:date-search-begin>
      <xocs:year-nav>2021</xocs:year-nav>
      <xocs:indexeddate epoch="1622080937">2021-05-27T02:02:17.782929Z</xocs:indexeddate>
      <xocs:articleinfo>absattachment aiptxt articleinfo articletitlenorm authfirstinitialnorm authfirstsurnamenorm cid cids contenttype copyright crossmark dateloaded dateloadedtxt datesearch datesort dateupdated dco docsubtype doctype doi eid ewtransactionid indexeddate issn issnnorm itemstage itemtransactionid itemweight openaccess openarchive pii piinorm pubdatestart pubdatetxt pubyr sortorder srctitle srctitlenorm srctype ssids alllist content subj subheadings tomb webpdf webpdfpagecount yearnav figure body acknowledge affil articletitle auth authfirstini authfull authlast footnotes grantnumber grantsponsor grantsponsorid highlightsabst orcid primabst pubtype ref specialabst</xocs:articleinfo>
      <xocs:issns>
         <xocs:issn-primary-formatted>1359-6446</xocs:issn-primary-formatted>
         <xocs:issn-primary-unformatted>13596446</xocs:issn-primary-unformatted>
      </xocs:issns>
      <xocs:crossmark is-crossmark="0"/></xocs:crossmark>
      <xocs:aip-text>In Press, Corrected Proof</xocs:aip-text>
      <xocs:sort-order>0</xocs:sort-order>
      <xocs:cover-date-text>Available online 27 May 2021</xocs:cover-date-text>
      <xocs:cover-date-start>2021-05-27</xocs:cover-date-start>
      <xocs:cover-date-year>2021</xocs:cover-date-year>
      <xocs:document-type>article</xocs:document-type>
      <xocs:document-subtype>rev</xocs:document-subtype>
      <xocs:copyright-line>Â© 2021 Published by Elsevier Ltd.</xocs:copyright-line>
      <xocs:normalized-article-title>TANKBINDINGKINASE1TBK1EMERGINGTHERAPEUTICTARGETFORDRUGDISCOVERY</xocs:normalized-article-title>
      <xocs:normalized-first-auth-surname>XIANG</xocs:normalized-first-auth-surname>
      <xocs:normalized-first-auth-initial>S</xocs:normalized-first-auth-initial>
      <xocs:item-toc>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Structure and mechanism of activation of TBK1</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Biological functions of TBK1</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>TBK1 in innate immunity</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>TBK1 in human cancer</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>TBK1 in autophagy</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>TBK1 in antitumor immunity</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>TBK1 in metabolic diseases</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Small-molecule inhibitors of TBK1</xocs:item-toc-section-title>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Amlexanox</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Aminopyrimidines</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
            <xocs:item-toc-entry ref-elem="ce:sections">
               <xocs:item-toc-section-title>Others</xocs:item-toc-section-title>
            </xocs:item-toc-entry>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:sections">
            <xocs:item-toc-section-title>Concluding remarks</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:acknowledgment">
            <xocs:item-toc-section-title>Acknowledgments</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
         <xocs:item-toc-entry ref-elem="ce:bibliography">
            <xocs:item-toc-section-title>References</xocs:item-toc-section-title>
         </xocs:item-toc-entry>
      </xocs:item-toc>
      <xocs:references>
         <xocs:ref-info refid="h0005">
            <xocs:ref-normalized-surname>POMERANTZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1999</xocs:ref-pub-year>
            <xocs:ref-first-fp>6694</xocs:ref-first-fp>
            <xocs:ref-last-lp>6704</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0010">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-article-number>979105</xocs:ref-article-number>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0015">
            <xocs:ref-normalized-surname>HAMMAKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>610</xocs:ref-first-fp>
            <xocs:ref-last-lp>618</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0020">
            <xocs:ref-normalized-surname>CHAU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2008</xocs:ref-pub-year>
            <xocs:ref-first-fp>171</xocs:ref-first-fp>
            <xocs:ref-last-lp>180</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0025">
            <xocs:ref-normalized-surname>WILD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>228</xocs:ref-first-fp>
            <xocs:ref-last-lp>233</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0030">
            <xocs:ref-normalized-surname>FITZGERALD</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>491</xocs:ref-first-fp>
            <xocs:ref-last-lp>496</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0035">
            <xocs:ref-normalized-surname>HASAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>336</xocs:ref-first-fp>
            <xocs:ref-last-lp>342</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0040">
            <xocs:ref-normalized-surname>MATSUMOTO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>4429</xocs:ref-first-fp>
            <xocs:ref-last-lp>4442</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0045">
            <xocs:ref-normalized-surname>RICHTER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>4039</xocs:ref-first-fp>
            <xocs:ref-last-lp>4044</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0050">
            <xocs:ref-normalized-surname>BARBIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>108</xocs:ref-first-fp>
            <xocs:ref-last-lp>112</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0055">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>520</xocs:ref-first-fp>
            <xocs:ref-last-lp>530</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0060">
            <xocs:ref-normalized-surname>XIAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1493</xocs:ref-first-fp>
            <xocs:ref-last-lp>1507</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0065">
            <xocs:ref-normalized-surname>EGUCHI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>14</xocs:ref-first-fp>
            <xocs:ref-last-lp>23</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0070">
            <xocs:ref-normalized-surname>XU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>15587</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0075">
            <xocs:ref-normalized-surname>LARABI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>734</xocs:ref-first-fp>
            <xocs:ref-last-lp>746</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0080">
            <xocs:ref-normalized-surname>TU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>747</xocs:ref-first-fp>
            <xocs:ref-last-lp>758</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0085">
            <xocs:ref-normalized-surname>MA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>9378</xocs:ref-first-fp>
            <xocs:ref-last-lp>9383</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0090">
            <xocs:ref-normalized-surname>HELGASON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1230</xocs:ref-first-fp>
            <xocs:ref-last-lp>1237</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0095">
            <xocs:ref-normalized-surname>LEI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>878</xocs:ref-first-fp>
            <xocs:ref-last-lp>889</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0100">
            <xocs:ref-normalized-surname>GU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>2553</xocs:ref-first-fp>
            <xocs:ref-last-lp>2565</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0105">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>eaae0435</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0110">
            <xocs:ref-normalized-surname>ZHAO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>731</xocs:ref-first-fp>
            <xocs:ref-last-lp>743</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>P</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0115">
            <xocs:ref-normalized-surname>JANEWAY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1989</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>13</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0120">
            <xocs:ref-normalized-surname>BRUBAKER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>257</xocs:ref-first-fp>
            <xocs:ref-last-lp>290</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0125">
            <xocs:ref-normalized-surname>SHARMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>1148</xocs:ref-first-fp>
            <xocs:ref-last-lp>1151</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0130">
            <xocs:ref-normalized-surname>YAMAMOTO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2003</xocs:ref-pub-year>
            <xocs:ref-first-fp>640</xocs:ref-first-fp>
            <xocs:ref-last-lp>643</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0135">
            <xocs:ref-normalized-surname>DEMPSEY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>146</xocs:ref-first-fp>
            <xocs:ref-last-lp>152</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0140">
            <xocs:ref-normalized-surname>ZHANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>394</xocs:ref-first-fp>
            <xocs:ref-last-lp>398</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0145">
            <xocs:ref-normalized-surname>CAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>289</xocs:ref-first-fp>
            <xocs:ref-last-lp>296</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>X</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0150">
            <xocs:ref-normalized-surname>HEMMI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>1641</xocs:ref-first-fp>
            <xocs:ref-last-lp>1650</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0155">
            <xocs:ref-normalized-surname>CHIEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2006</xocs:ref-pub-year>
            <xocs:ref-first-fp>157</xocs:ref-first-fp>
            <xocs:ref-last-lp>170</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0160">
            <xocs:ref-normalized-surname>KIM</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>12414</xocs:ref-first-fp>
            <xocs:ref-last-lp>12419</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0165">
            <xocs:ref-normalized-surname>PILLAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>10072</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0170">
            <xocs:ref-normalized-surname>ZHU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>452</xocs:ref-first-fp>
            <xocs:ref-last-lp>465</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0175">
            <xocs:ref-normalized-surname>KITAJIMA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>439</xocs:ref-first-fp>
            <xocs:ref-last-lp>452</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0180">
            <xocs:ref-normalized-surname>YING</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>355</xocs:ref-first-fp>
            <xocs:ref-last-lp>385</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0185">
            <xocs:ref-normalized-surname>CRUZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>e126117</xocs:ref-article-number>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0190">
            <xocs:ref-normalized-surname>OU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>458</xocs:ref-first-fp>
            <xocs:ref-last-lp>470</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Y</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0195">
            <xocs:ref-normalized-surname>MUVAFFAK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1055</xocs:ref-first-fp>
            <xocs:ref-last-lp>1066</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0200">
            <xocs:ref-normalized-surname>HU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>460</xocs:ref-first-fp>
            <xocs:ref-last-lp>475</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0205">
            <xocs:ref-normalized-surname>GNARRA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>1994</xocs:ref-pub-year>
            <xocs:ref-first-fp>85</xocs:ref-first-fp>
            <xocs:ref-last-lp>90</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0210">
            <xocs:ref-normalized-surname>LEVINE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2004</xocs:ref-pub-year>
            <xocs:ref-first-fp>463</xocs:ref-first-fp>
            <xocs:ref-last-lp>477</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>B</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0215">
            <xocs:ref-normalized-surname>RYBSTEIN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>243</xocs:ref-first-fp>
            <xocs:ref-last-lp>251</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0220"/></xocs:ref-info>
         <xocs:ref-info refid="h0225">
            <xocs:ref-normalized-surname>FIMIA</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>1</xocs:ref-first-fp>
            <xocs:ref-last-lp>2</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>G</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0230">
            <xocs:ref-normalized-surname>PILLI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>223</xocs:ref-first-fp>
            <xocs:ref-last-lp>234</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0235">
            <xocs:ref-normalized-surname>LI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2016</xocs:ref-pub-year>
            <xocs:ref-first-fp>12708</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>F</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0240">
            <xocs:ref-normalized-surname>GERBINO</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>789</xocs:ref-first-fp>
            <xocs:ref-last-lp>805</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>V</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0245">
            <xocs:ref-normalized-surname>BLOKHUIS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>777</xocs:ref-first-fp>
            <xocs:ref-last-lp>794</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0250">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>276</xocs:ref-first-fp>
            <xocs:ref-last-lp>287</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0255">
            <xocs:ref-normalized-surname>YANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>717</xocs:ref-first-fp>
            <xocs:ref-last-lp>729</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0260">
            <xocs:ref-normalized-surname>MAUERODER</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>212</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0265">
            <xocs:ref-normalized-surname>JENKINS</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>196</xocs:ref-first-fp>
            <xocs:ref-last-lp>215</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0270">
            <xocs:ref-normalized-surname>ZHU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>1604</xocs:ref-first-fp>
            <xocs:ref-last-lp>1614</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0275">
            <xocs:ref-normalized-surname>CHIANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>961</xocs:ref-first-fp>
            <xocs:ref-last-lp>975</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0280"/></xocs:ref-info>
         <xocs:ref-info refid="h0285">
            <xocs:ref-normalized-surname>YEHUDASHNAIDMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2010</xocs:ref-pub-year>
            <xocs:ref-first-fp>2474</xocs:ref-first-fp>
            <xocs:ref-last-lp>2483</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0290">
            <xocs:ref-normalized-surname>REILLY</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2013</xocs:ref-pub-year>
            <xocs:ref-first-fp>313</xocs:ref-first-fp>
            <xocs:ref-last-lp>321</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>S</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0295">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>943</xocs:ref-first-fp>
            <xocs:ref-last-lp>957</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>C</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0300">
            <xocs:ref-normalized-surname>MUNOZ</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>185</xocs:ref-first-fp>
            <xocs:ref-last-lp>197</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0305">
            <xocs:ref-normalized-surname>HUH</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>1012</xocs:ref-first-fp>
            <xocs:ref-last-lp>1027</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0310">
            <xocs:ref-normalized-surname>HE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>117010</xocs:ref-article-number>
            <xocs:ref-normalized-initial>Q</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0315">
            <xocs:ref-normalized-surname>BEYETT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>1210</xocs:ref-first-fp>
            <xocs:ref-last-lp>1219</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0320">
            <xocs:ref-normalized-surname>ORAL</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>157</xocs:ref-first-fp>
            <xocs:ref-last-lp>170</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0325">
            <xocs:ref-normalized-surname>QI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-article-number>114767</xocs:ref-article-number>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0330">
            <xocs:ref-normalized-surname>ZHOU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-first-fp>1383</xocs:ref-first-fp>
            <xocs:ref-last-lp>1398</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>Z</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0335">
            <xocs:ref-normalized-surname>BEYETT</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>5443</xocs:ref-first-fp>
            <xocs:ref-last-lp>5461</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0340">
            <xocs:ref-normalized-surname>FELDMAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2005</xocs:ref-pub-year>
            <xocs:ref-first-fp>19867</xocs:ref-first-fp>
            <xocs:ref-last-lp>19874</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>R</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0345">
            <xocs:ref-normalized-surname>CLARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>14136</xocs:ref-first-fp>
            <xocs:ref-last-lp>14146</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0350">
            <xocs:ref-normalized-surname>YU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2020</xocs:ref-pub-year>
            <xocs:ref-article-number>113797</xocs:ref-article-number>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0355">
            <xocs:ref-normalized-surname>JAISHANKAR</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>eaan5861</xocs:ref-first-fp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0360">
            <xocs:ref-normalized-surname>BAI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>287</xocs:ref-first-fp>
            <xocs:ref-last-lp>296</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>L</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0365">
            <xocs:ref-normalized-surname>CHEN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2017</xocs:ref-pub-year>
            <xocs:ref-first-fp>1892</xocs:ref-first-fp>
            <xocs:ref-last-lp>1899</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>W</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0370">
            <xocs:ref-normalized-surname>CHOI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>82</xocs:ref-first-fp>
            <xocs:ref-last-lp>93</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>E</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0375">
            <xocs:ref-normalized-surname>CLARK</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2011</xocs:ref-pub-year>
            <xocs:ref-first-fp>93</xocs:ref-first-fp>
            <xocs:ref-last-lp>104</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0380">
            <xocs:ref-normalized-surname>PARDANANI</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2009</xocs:ref-pub-year>
            <xocs:ref-first-fp>1441</xocs:ref-first-fp>
            <xocs:ref-last-lp>1445</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0385">
            <xocs:ref-normalized-surname>BARBIE</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>853</xocs:ref-first-fp>
            <xocs:ref-last-lp>859</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0390">
            <xocs:ref-normalized-surname>NG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>159</xocs:ref-first-fp>
            <xocs:ref-last-lp>165</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>K</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0395">
            <xocs:ref-normalized-surname>THOMSON</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>780</xocs:ref-first-fp>
            <xocs:ref-last-lp>785</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>D</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0400">
            <xocs:ref-normalized-surname>WANG</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2012</xocs:ref-pub-year>
            <xocs:ref-first-fp>2063</xocs:ref-first-fp>
            <xocs:ref-last-lp>2069</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>T</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0405">
            <xocs:ref-normalized-surname>JOHANNES</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1138</xocs:ref-first-fp>
            <xocs:ref-last-lp>1143</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0410">
            <xocs:ref-normalized-surname>VU</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2014</xocs:ref-pub-year>
            <xocs:ref-first-fp>1509</xocs:ref-first-fp>
            <xocs:ref-last-lp>1519</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>H</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0415">
            <xocs:ref-normalized-surname>HASAN</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2015</xocs:ref-pub-year>
            <xocs:ref-first-fp>4573</xocs:ref-first-fp>
            <xocs:ref-last-lp>4577</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>M</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0420">
            <xocs:ref-normalized-surname>LEFRANC</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2019</xocs:ref-pub-year>
            <xocs:ref-first-fp>601</xocs:ref-first-fp>
            <xocs:ref-last-lp>612</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>J</xocs:ref-normalized-initial>
         </xocs:ref-info>
         <xocs:ref-info refid="h0425">
            <xocs:ref-normalized-surname>CREW</xocs:ref-normalized-surname>
            <xocs:ref-pub-year>2018</xocs:ref-pub-year>
            <xocs:ref-first-fp>583</xocs:ref-first-fp>
            <xocs:ref-last-lp>598</xocs:ref-last-lp>
            <xocs:ref-normalized-initial>A</xocs:ref-normalized-initial>
         </xocs:ref-info>
      </xocs:references>
      <xocs:refkeys/></xocs:refkeys>
      <xocs:open-access>
         <xocs:oa-article-status is-open-access="0" is-open-archive="0"/></xocs:oa-article-status>
      </xocs:open-access>
      <xocs:copyright-info>
         <xocs:cp-notices>
            <xocs:cp-notice lang="en">Â© 2021 Published by Elsevier Ltd.</xocs:cp-notice>
         </xocs:cp-notices>
      </xocs:copyright-info>
      <xocs:funding-list has-funding-info="1">
         <xocs:funding-addon-generated-timestamp>2021-05-26T18:22:10.305Z</xocs:funding-addon-generated-timestamp>
         <xocs:funding-addon-type>http://vtw.elsevier.com/data/voc/AddOnTypes/50.7/nlp</xocs:funding-addon-type>
         <xocs:funding-source-document source-document-type="pii">S1359644621002488</xocs:funding-source-document>
         <xocs:funding>
            <xocs:funding-agency-matched-string>Health Research Council of New Zealand</xocs:funding-agency-matched-string>
            <xocs:funding-id>18/1016</xocs:funding-id>
            <xocs:funding-agency-acronym>HRC</xocs:funding-agency-acronym>
            <xocs:funding-agency>Health Research Council of New Zealand</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100001505</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/2186224/</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-matched-string>National Natural Science Foundation of China</xocs:funding-agency-matched-string>
            <xocs:funding-id>81922062</xocs:funding-id>
            <xocs:funding-agency-acronym>NSFC</xocs:funding-agency-acronym>
            <xocs:funding-agency>National Natural Science Foundation of China</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100001809</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991/</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding>
            <xocs:funding-agency-matched-string>National Key Research and Development Program of China</xocs:funding-agency-matched-string>
            <xocs:funding-id>2018YFE0105800</xocs:funding-id>
            <xocs:funding-agency-acronym>NKRDPC</xocs:funding-agency-acronym>
            <xocs:funding-agency>National Key Research and Development Program of China</xocs:funding-agency>
            <xocs:funding-agency-id>http://data.elsevier.com/vocabulary/SciValFunders/501100012166</xocs:funding-agency-id>
            <xocs:funding-agency-country>http://sws.geonames.org/1814991/</xocs:funding-agency-country>
         </xocs:funding>
         <xocs:funding-text>We appreciate the financial support from National Natural Science Foundation of China (81922062), National Key Research and Development Program of China (2018YFE0105800) and the Health Research Council of New Zealand (18/1016). </xocs:funding-text>
      </xocs:funding-list>
      <xocs:attachment-metadata-doc>
         <xocs:attachment-set-type>item</xocs:attachment-set-type>
         <xocs:pii-formatted>S1359-6446(21)00248-8</xocs:pii-formatted>
         <xocs:pii-unformatted>S1359644621002488</xocs:pii-unformatted>
         <xocs:eid>1-s2.0-S1359644621002488</xocs:eid>
         <xocs:doi>10.1016/j.drudis.2021.05.016</xocs:doi>
         <xocs:cid>271275</xocs:cid>
         <xocs:timestamp>2021-06-10T01:22:19.515103Z</xocs:timestamp>
         <xocs:cover-date-start>2021-05-27</xocs:cover-date-start>
         <xocs:attachments>
            <xocs:web-pdf>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-main.pdf</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/MAIN/application/pdf/08c4438b26d0ab8074b7091a33e4eb8b/main.pdf</xocs:ucs-locator>
               <xocs:filename>main.pdf</xocs:filename>
               <xocs:extension>pdf</xocs:extension>
               <xocs:pdf-optimized>true</xocs:pdf-optimized>
               <xocs:filesize>1969723</xocs:filesize>
               <xocs:web-pdf-purpose>MAIN</xocs:web-pdf-purpose>
               <xocs:web-pdf-page-count>11</xocs:web-pdf-page-count>
               <xocs:web-pdf-images>
                  <xocs:web-pdf-image>
                     <xocs:attachment-eid>1-s2.0-S1359644621002488-main_1.png</xocs:attachment-eid>
                     <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/PREVIEW/image/png/d517c2a3da38220c044096a3c6c0f95d/main_1.png</xocs:ucs-locator>
                     <xocs:filename>main_1.png</xocs:filename>
                     <xocs:extension>png</xocs:extension>
                     <xocs:filesize>97401</xocs:filesize>
                     <xocs:pixel-height>849</xocs:pixel-height>
                     <xocs:pixel-width>656</xocs:pixel-width>
                     <xocs:attachment-type>IMAGE-WEB-PDF</xocs:attachment-type>
                     <xocs:pdf-page-num>1</xocs:pdf-page-num>
                  </xocs:web-pdf-image>
               </xocs:web-pdf-images>
            </xocs:web-pdf>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-ga1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/ga1/DOWNSAMPLED/image/jpeg/065813a5e6f2335f92c1e53d134494e2/ga1.jpg</xocs:ucs-locator>
               <xocs:file-basename>ga1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>ga1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>18635</xocs:filesize>
               <xocs:pixel-height>200</xocs:pixel-height>
               <xocs:pixel-width>282</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr1.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr1/DOWNSAMPLED/image/jpeg/62e46ca3763e2b192b93e1f08d4eedcf/gr1.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>111861</xocs:filesize>
               <xocs:pixel-height>717</xocs:pixel-height>
               <xocs:pixel-width>788</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr2.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr2/DOWNSAMPLED/image/jpeg/343610a42c92713f1ba0b0bdfcd93da7/gr2.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>65225</xocs:filesize>
               <xocs:pixel-height>437</xocs:pixel-height>
               <xocs:pixel-width>752</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr3.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr3/DOWNSAMPLED/image/jpeg/db9c51e6c117f913ec9304d1c0c8164c/gr3.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>26565</xocs:filesize>
               <xocs:pixel-height>313</xocs:pixel-height>
               <xocs:pixel-width>556</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr4a.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr4a/DOWNSAMPLED/image/jpeg/d47474198eea566d0315eda2ed726385/gr4a.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4a</xocs:file-basename>
               <xocs:filename>gr4a.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>49961</xocs:filesize>
               <xocs:pixel-height>397</xocs:pixel-height>
               <xocs:pixel-width>706</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr4b.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr4b/DOWNSAMPLED/image/jpeg/ca89fec72b01ea11fdcdad5861dc0aec/gr4b.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4b</xocs:file-basename>
               <xocs:filename>gr4b.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>36974</xocs:filesize>
               <xocs:pixel-height>385</xocs:pixel-height>
               <xocs:pixel-width>689</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr6.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr6/DOWNSAMPLED/image/jpeg/042fdedbbe02ed62acb821cf5d5ccbd2/gr6.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>64877</xocs:filesize>
               <xocs:pixel-height>409</xocs:pixel-height>
               <xocs:pixel-width>576</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr5.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr5/DOWNSAMPLED/image/jpeg/13ca7e9376f50c14963216f3ee50e3a9/gr5.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>60767</xocs:filesize>
               <xocs:pixel-height>381</xocs:pixel-height>
               <xocs:pixel-width>622</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-DOWNSAMPLED</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-ga1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/ga1/THUMBNAIL/image/gif/8d00b1f20e3a9a522ac0fbb836921fc3/ga1.sml</xocs:ucs-locator>
               <xocs:file-basename>ga1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>ga1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>11541</xocs:filesize>
               <xocs:pixel-height>155</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr1.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr1/THUMBNAIL/image/gif/901202cedf82b4d91d68103f2fb250e6/gr1.sml</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>10529</xocs:filesize>
               <xocs:pixel-height>164</xocs:pixel-height>
               <xocs:pixel-width>180</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr2.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr2/THUMBNAIL/image/gif/1d5da135a81cb15a516cc14ac7784aa4/gr2.sml</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>8390</xocs:filesize>
               <xocs:pixel-height>127</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr3.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr3/THUMBNAIL/image/gif/b453f66585bc92c35a2c9878fd273c4b/gr3.sml</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5694</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr4a.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr4a/THUMBNAIL/image/gif/21ab0439c3401a4721ec3d40c0c8e37f/gr4a.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4a</xocs:file-basename>
               <xocs:filename>gr4a.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7700</xocs:filesize>
               <xocs:pixel-height>123</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr4b.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr4b/THUMBNAIL/image/gif/f1255045e2e083130c67f72d9672a302/gr4b.sml</xocs:ucs-locator>
               <xocs:file-basename>gr4b</xocs:file-basename>
               <xocs:filename>gr4b.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>5685</xocs:filesize>
               <xocs:pixel-height>122</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr6.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr6/THUMBNAIL/image/gif/964072f7e6ac62923ed8aa0114e11cb1/gr6.sml</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>13298</xocs:filesize>
               <xocs:pixel-height>156</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr5.sml</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr5/THUMBNAIL/image/gif/206b408a5e5fb8f620d9116938582f71/gr5.sml</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5.sml</xocs:filename>
               <xocs:extension>sml</xocs:extension>
               <xocs:filesize>7216</xocs:filesize>
               <xocs:pixel-height>134</xocs:pixel-height>
               <xocs:pixel-width>219</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-THUMBNAIL</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-ga1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/ga1/HIGHRES/image/jpeg/8eb779d6de0af276a9157a29a955e20b/ga1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>ga1</xocs:file-basename>
               <xocs:abstract-attachment>true</xocs:abstract-attachment>
               <xocs:filename>ga1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>136071</xocs:filesize>
               <xocs:pixel-height>886</xocs:pixel-height>
               <xocs:pixel-width>1248</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr1_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr1/HIGHRES/image/jpeg/a908865bb97308673fd4f92698c347a5/gr1_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr1</xocs:file-basename>
               <xocs:filename>gr1_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>757965</xocs:filesize>
               <xocs:pixel-height>3176</xocs:pixel-height>
               <xocs:pixel-width>3489</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr2_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr2/HIGHRES/image/jpeg/b3560f24341b42feddd713b727e29b29/gr2_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr2</xocs:file-basename>
               <xocs:filename>gr2_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>471061</xocs:filesize>
               <xocs:pixel-height>1936</xocs:pixel-height>
               <xocs:pixel-width>3331</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr3_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr3/HIGHRES/image/jpeg/ec9a890d41ceabb112da1f3503ea34ec/gr3_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr3</xocs:file-basename>
               <xocs:filename>gr3_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>188429</xocs:filesize>
               <xocs:pixel-height>1384</xocs:pixel-height>
               <xocs:pixel-width>2461</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr4a_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr4a/HIGHRES/image/jpeg/a57b4485a0196fd0a807f9c02dc1888c/gr4a_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4a</xocs:file-basename>
               <xocs:filename>gr4a_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>379190</xocs:filesize>
               <xocs:pixel-height>1760</xocs:pixel-height>
               <xocs:pixel-width>3126</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr4b_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr4b/HIGHRES/image/jpeg/ca905608676f7aaff3f1f9aa12af54b5/gr4b_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr4b</xocs:file-basename>
               <xocs:filename>gr4b_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>276137</xocs:filesize>
               <xocs:pixel-height>1704</xocs:pixel-height>
               <xocs:pixel-width>3051</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr6_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr6/HIGHRES/image/jpeg/35846a528804bc7a75654d9cb3f2fe2f/gr6_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr6</xocs:file-basename>
               <xocs:filename>gr6_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>430491</xocs:filesize>
               <xocs:pixel-height>1814</xocs:pixel-height>
               <xocs:pixel-width>2552</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
            <xocs:attachment>
               <xocs:attachment-eid>1-s2.0-S1359644621002488-gr5_lrg.jpg</xocs:attachment-eid>
               <xocs:ucs-locator>https://s3-eu-west-1.amazonaws.com/prod-ucs-content-store-eu-west/content/pii:S1359644621002488/gr5/HIGHRES/image/jpeg/c2ad6c2baedf5272fe7b63773aeaf6dd/gr5_lrg.jpg</xocs:ucs-locator>
               <xocs:file-basename>gr5</xocs:file-basename>
               <xocs:filename>gr5_lrg.jpg</xocs:filename>
               <xocs:extension>jpg</xocs:extension>
               <xocs:filesize>409032</xocs:filesize>
               <xocs:pixel-height>1688</xocs:pixel-height>
               <xocs:pixel-width>2756</xocs:pixel-width>
               <xocs:attachment-type>IMAGE-HIGH-RES</xocs:attachment-type>
            </xocs:attachment>
         </xocs:attachments>
      </xocs:attachment-metadata-doc>
   </xocs:meta><xocs:serial-item xmlns:xoe="http://www.elsevier.com/xml/xoe/dtd">
      <article xmlns="http://www.elsevier.com/xml/ja/dtd" docsubtype="rev" version="5.6" xml:lang="en">
         <item-info>
            <jid>DRUDIS</jid>
            <aid>3030</aid>
            <ce:pii>S1359-6446(21)00248-8</ce:pii>
            <ce:doi>10.1016/j.drudis.2021.05.016</ce:doi>
            <ce:copyright type="unknown" year="2021"/></ce:copyright>
         </item-info>
         <ce:floats>
            <ce:figure id="f0005">
               <ce:label>Figure 1</ce:label>
               <ce:caption id="cn0005">
                  <ce:simple-para id="sp0020" view="all">Overview of the structure and mechanism of activation of TANK-binding kinase 1 (TBK1). (a) A cartoon showing the four domains of human TBK1: N-terminal kinase domain (KD), a ubiquitin-like domain (ULD), an Î±-helical scaffold dimerization domain (SDD), and a C-terminal adaptor-binding domain (CTD). (b) (i) The compact dimerization structure of TBK1. The twofold symmetry axis is indicated by a dotted line. (ii) The activated kinase domain of TBK1. The Î±C-helix rotates to the inward active site position, allowing Glu55 to form a salt bridge with Lys38. The hydrogen-bonding network between p-Ser172 and Arg54, Arg134, and Arg162 stabilizes the active conformation of the kinase. (c) Model of TBK1 activation by <ce:italic>trans</ce:italic>-phosphorylation.</ce:simple-para>
               </ce:caption>
               <ce:link id="lk00005" locator="gr1" xlink:href="pii:S1359644621002488/gr1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="f0010">
               <ce:label>Figure 2</ce:label>
               <ce:caption id="cn0010">
                  <ce:simple-para id="sp0025" view="all">TANK-binding kinase 1 (TBK1) regulates the release of type I interferon (IFN) in the innate immune system. Pattern recognition receptors [Toll-like receptors (TLRs), RIG-1-like receptors (RLRs), or cytoplasmic DNA sensors] can recognize different pathogen-associated molecular patterns [lipopolysaccharide (LPS), viral double-stranded (ds)DNA or RNA], thereby recruiting adaptors [TIR-domain-containing adaptor-inducing IFN-Î² (TRIF), tumor necrosis factor receptor-associated factor (TRAF), TRIF-related adaptor molecule (TRAM), or stimulator of the IFN gene (STING)] to activate TBK1 kinase. Activated TBK1 can phosphorylate IFN-regulatory factor 3 and 7 (IRF3 and IRF7), leading to their homodimerization and translocation to the nucleus, thereby driving the production of antiviral type I IFN.</ce:simple-para>
               </ce:caption>
               <ce:link id="lk00010" locator="gr2" xlink:href="pii:S1359644621002488/gr2" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="f0015">
               <ce:label>Figure 3</ce:label>
               <ce:caption id="cn0015">
                  <ce:simple-para id="sp0030" view="all">Diverse roles of TANK-binding kinase 1 (TBK1) kinase in cancer. TBK1 is involved in the regulation of mitosis through Polo-like kinase 1 (PLK1) phosphorylation. The RalB/Sec5 complex downstream of KRAS directly recruits and activates TBK1; activated TBK1 can promote a non-small cell lung cancer (NSCLC)-dependent autocrine cytokine circuit and pancreatic cancer cell epithelial-mesenchymal transition (EMT). TBK1 can also regulate pancreatic ductal adenocarcinoma (PDAC)-dependent basic autophagy. In addition, TBK1 maintains T cell homeostasis and contributes to tumor immune tolerance.</ce:simple-para>
               </ce:caption>
               <ce:link id="lk00015" locator="gr3" xlink:href="pii:S1359644621002488/gr3" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="f0020">
               <ce:label>Figure 4</ce:label>
               <ce:caption id="cn0020">
                  <ce:simple-para id="sp0035" view="all">TANK-binding kinase 1 (TBK1) and inhibitor-kappaB kinase Îµ (IKKÎµ) mediate the pathways of obesity and Î² cell proliferation. (a) In adipocytes, TBK1 and IKKÎµ are activated in the nuclear factor (NF)-ÎºB pathway mediated by a high-fat diet (HFD) and tumor necrosis factor (TNF)-Î±. Activated TBK1 and IKKÎµ act on downstream targets [phosphodiesterase 3B (PDE3B), AMP kinase (AMPK), and cAMP], and inhibit uncoupling protein 1 (UCP1) and protein kinase A (PKA) to reduce energy expenditure, thermogenesis, and lipolysis. (b) In pancreatic Î²- cells, PDE3B activated by TBK1 inhibits the cAMP-PKA-mammalian target of rapamycin (mTOR) pathway and blocks Î² cell replication.</ce:simple-para>
               </ce:caption>
               <ce:link id="lk00020" locator="gr4a" xlink:href="pii:S1359644621002488/gr4a" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
               <ce:link id="lk00025" locator="gr4b" xlink:href="pii:S1359644621002488/gr4b" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="f0025">
               <ce:label>Figure 5</ce:label>
               <ce:caption id="cn0025">
                  <ce:simple-para id="sp0040" view="all">Representative structures of TANK-binding kinase 1 (TBK1) inhibitors. (a) amlexanox (1), and analogs (2, 3, and 4). (b) Aminopyrimidine derivatives BX795 (5), MRT67307 (6), CYT387 (7), and GSK8612 (8). (c) Imidazopyridine (9) and AZ3102909 (10), compound II (11), and BAY985 (12).</ce:simple-para>
               </ce:caption>
               <ce:link id="lk00030" locator="gr5" xlink:href="pii:S1359644621002488/gr5" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
            <ce:figure id="f0030">
               <ce:label>Figure 6</ce:label>
               <ce:caption id="cn0030">
                  <ce:simple-para id="sp0045" view="all">The X-ray crystal structure of TANK-binding kinase 1 (TBK1) with representative compounds. The binding mode of TBK1 in complex with (a) amlexanox (1) [Protein Data Bank (PDB): 5W5V], (b) BX795 (5) (PDB: 4IW0), and (c) MRT67307 (6) (PDB: 4IM0). (d) The docked binding mode of TBK1 in complex with BAY-985 (12). The key residues are represented as blue sticks. Hydrogen bonds are shown as yellow dashes.</ce:simple-para>
               </ce:caption>
               <ce:link id="lk00035" locator="gr6" xlink:href="pii:S1359644621002488/gr6" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:link>
            </ce:figure>
         </ce:floats>
         <head>
            <ce:dochead id="dh005">
               <ce:textfn>Post-screen (grey)</ce:textfn>
            </ce:dochead>
            <ce:title id="tm005">TANK-binding kinase 1 (TBK1): An emerging therapeutic target for drug discovery</ce:title>
            <ce:author-group id="ag005">
               <ce:author id="au005" author-id="S1359644621002488-1657f9a773652cc67bee83a3a4cc480f">
                  <ce:given-name>Shuang</ce:given-name>
                  <ce:surname>Xiang</ce:surname>
                  <ce:cross-ref id="c0005" refid="af005">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="c0010" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au010" author-id="S1359644621002488-94d77b34ded40ac20a400376acb11216">
                  <ce:given-name>Shukai</ce:given-name>
                  <ce:surname>Song</ce:surname>
                  <ce:cross-ref id="c0015" refid="af005">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="c0020" refid="fn1">
                     <ce:sup loc="post">1</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au015" author-id="S1359644621002488-c527d1592615579316e10c32a6aab7f5">
                  <ce:given-name>Haotian</ce:given-name>
                  <ce:surname>Tang</ce:surname>
                  <ce:cross-ref id="c0025" refid="af010">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au020" orcid="0000-0003-2954-6093" author-id="S1359644621002488-8b912cbad3ca80ecb84d794726a3b618">
                  <ce:given-name>Jeff B.</ce:given-name>
                  <ce:surname>Smaill</ce:surname>
                  <ce:cross-ref id="c0030" refid="af015">
                     <ce:sup loc="post">c</ce:sup>
                  </ce:cross-ref>
               </ce:author>
               <ce:author id="au025" author-id="S1359644621002488-c78c3594660f189aa0ab2562938a3397">
                  <ce:given-name>Aiqun</ce:given-name>
                  <ce:surname>Wang</ce:surname>
                  <ce:cross-ref id="c0035" refid="af020">
                     <ce:sup loc="post">d</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="c0040" refid="cor1">
                     <ce:sup loc="post">â</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au030" author-id="S1359644621002488-da8dd71a34d2cc03cd9b5479c2d01cbd">
                  <ce:given-name>Hua</ce:given-name>
                  <ce:surname>Xie</ce:surname>
                  <ce:cross-ref id="c0045" refid="af010">
                     <ce:sup loc="post">b</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="c0050" refid="cor1">
                     <ce:sup loc="post">â</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:author id="au035" author-id="S1359644621002488-dbb42ab6b408f579f1f039a9792f0a80">
                  <ce:given-name>Xiaoyun</ce:given-name>
                  <ce:surname>Lu</ce:surname>
                  <ce:cross-ref id="c0055" refid="af005">
                     <ce:sup loc="post">a</ce:sup>
                  </ce:cross-ref>
                  <ce:cross-ref id="c0060" refid="cor1">
                     <ce:sup loc="post">â</ce:sup>
                  </ce:cross-ref>
                  
               </ce:author>
               <ce:affiliation id="af005" affiliation-id="S1359644621002488-411b9675f61eb08a2a19af2cf667af90">
                  <ce:label>a</ce:label>
                  <ce:textfn>Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Jinan University</sa:organization>
                     <sa:address-line>601 Huangpu Avenue West</sa:address-line>
                     <sa:city>Guangzhou</sa:city>
                     <sa:postal-code>510632</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="stx005">Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="af010" affiliation-id="S1359644621002488-295e29ad0b979b87d22839bb1cfdf97c">
                  <ce:label>b</ce:label>
                  <ce:textfn>Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Division of Antitumor Pharmacology</sa:organization>
                     <sa:organization>State Key Laboratory of Drug Research</sa:organization>
                     <sa:organization>Shanghai Institute of Materia Medica</sa:organization>
                     <sa:organization>Chinese Academy of Sciences</sa:organization>
                     <sa:address-line>555 Zuchongzhi Road</sa:address-line>
                     <sa:city>Shanghai</sa:city>
                     <sa:postal-code>201203</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="stx010">Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="af015" affiliation-id="S1359644621002488-fc67c9d76a9f4a11b7d8381018665b3d">
                  <ce:label>c</ce:label>
                  <ce:textfn>Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Auckland Cancer Society Research Centre</sa:organization>
                     <sa:organization>School of Medical Sciences</sa:organization>
                     <sa:organization>The University of Auckland</sa:organization>
                     <sa:address-line>Private Bag 92019</sa:address-line>
                     <sa:city>Auckland</sa:city>
                     <sa:postal-code>1142</sa:postal-code>
                     <sa:country>New Zealand</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="stx015">Auckland Cancer Society Research Centre, School of Medical Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand</ce:source-text>
               </ce:affiliation>
               <ce:affiliation id="af020" affiliation-id="S1359644621002488-0853a4823090e8e56f585170d5944a7f">
                  <ce:label>d</ce:label>
                  <ce:textfn>Department of Anesthesiology, Guangzhou Red Cross Hospital Affiliated to Jinan University, Guangzhou 510220, China</ce:textfn>
                  <sa:affiliation>
                     <sa:organization>Department of Anesthesiology</sa:organization>
                     <sa:organization>Guangzhou Red Cross Hospital Affiliated to Jinan University</sa:organization>
                     <sa:city>Guangzhou</sa:city>
                     <sa:postal-code>510220</sa:postal-code>
                     <sa:country>China</sa:country>
                  </sa:affiliation>
                  <ce:source-text id="stx020">Department of Anesthesiology, Guangzhou Red Cross Hospital Affiliated to Jinan University, Guangzhou 510220, China</ce:source-text>
               </ce:affiliation>
               <ce:correspondence id="cor1">
                  <ce:label>â</ce:label>
                  <ce:text>Corresponding authors.</ce:text>
               </ce:correspondence>
               <ce:footnote id="fn1">
                  <ce:label>1</ce:label>
                  <ce:note-para id="np005" view="all">These authors contributed equally.</ce:note-para>
               </ce:footnote>
            </ce:author-group>
            <ce:abstract class="graphical" id="ab005" xml:lang="en" view="all">
               <ce:section-title id="st005">Graphical abstract</ce:section-title>
               <ce:abstract-sec id="as005" view="all">
                  <ce:simple-para id="sp0005" view="all">
                     <ce:display>
                        <ce:figure id="f0035">
                           <ce:link id="lk00040" locator="ga1" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:href="pii:S1359644621002488/ga1"/></ce:link>
                        </ce:figure>
                     </ce:display>
                  </ce:simple-para>
               </ce:abstract-sec>
            </ce:abstract>
            
            <ce:abstract class="author" id="ab015" xml:lang="en" view="all"><ce:abstract-sec id="as015" view="all">
                  <ce:simple-para id="sp0015" view="all">Dysregulation of TANK-binding kinase 1 (TBK1) homeostasis leads to the occurrence and progression of many diseases, such as inflammation, autoimmune diseases, metabolic diseases, and cancer. Therefore, there is a need to develop TBK1 inhibitors as therapeutic agents. In this review, we highlight the diverse biological functions of TBK1 and summarize the promising small-molecule inhibitors of TBK1 that have the potential to be developed as therapeutic candidates.</ce:simple-para>
               </ce:abstract-sec></ce:abstract>
         </head>
         <body view="all">
            <ce:sections>
               <ce:para id="p0025" view="all">The inhibitor-kappaB kinase (IKK) family contains canonical and non-canonical IKK kinases. Canonical IKK kinases include IKKÎ±, IKKÎ², and IKKÎ³ (also known as NEMO), whereas non-canonical IKK kinases include IKKÎµ and TBK1. The kinase domain of TBK1 shares 49% identity and 65% similarity to that of IKKÎµ. Unsurprisingly, they have a variety of similar biological functions.<ce:cross-refs id="r0005" refid="b0005 b0010">
                     <ce:sup loc="post">1,2</ce:sup>
                  </ce:cross-refs> TBK1 is ubiquitously expressed in all tissues, whereas IKKÎµ expression is restricted to particular tissues, such as lymphoid tissues, peripheral blood lymphocytes, and the pancreas.<ce:cross-ref id="c0065" refid="b0015">
                     <ce:sup loc="post">3</ce:sup>
                  </ce:cross-ref> With a growing in-depth understanding of the structure and biological functions of non-canonical IKK kinases, TBK1 has attracted the interest as an emerging therapeutic target. TBK1 kinase resists and eliminates invading pathogens by mediating innate immunity and autophagy.<ce:cross-refs id="r0010" refid="b0020 b0025">
                     <ce:sup loc="post">4,5</ce:sup>
                  </ce:cross-refs> Similarly, the chronic activation of innate immune signals mediated by TBK1 can initiate an immune attack on the host, leading to organ damage and disease; thus, TBK1 is considered as a potential target for the treatment of inflammatory and autoimmune diseases.<ce:cross-refs id="r0015" refid="b0030 b0035">
                     <ce:sup loc="post">6,7</ce:sup>
                  </ce:cross-refs> TBK1-regulated autophagy has an important function in the elimination of damaged mitochondria.<ce:cross-refs id="r0020" refid="b0040 b0045">
                     <ce:sup loc="post">8,9</ce:sup>
                  </ce:cross-refs> Furthermore, with the identification of TBK1 as a carcinogenic KRAS synthetic lethal partner, several studies have focused on exploring the mechanism of TBK1-mediated tumorigenesis. The tumor-promoting effects of TBK1, via the novel KRAS effector pathway RalB-TBK1, have been investigated.<ce:cross-ref id="c0070" refid="b0050">
                     <ce:sup loc="post">10</ce:sup>
                  </ce:cross-ref> TBK1 also has a key role in maintaining tumor-dependent autophagy and cancer immune tolerance.<ce:cross-refs id="r0025" refid="b0055 b0060">
                     <ce:sup loc="post">11,12</ce:sup>
                  </ce:cross-refs> Therefore, targeting TBK1 provides new promise for the treatment of cancer, especially refractory cancers driven by oncogenic KRAS. In addition, some studies have linked TBK1 to metabolic diseases with chronic low-inflammatory characteristics, such as obesity and type 2 diabetes mellitus (T2DM).<ce:cross-refs id="r0030" refid="b0065 b0070">
                     <ce:sup loc="post">13,14</ce:sup>
                  </ce:cross-refs> Researchers have devoted significant effort toward the development of highly effective and specific TBK1 inhibitors in recent years. These inhibitors have shown potent efficacy <ce:italic>in vitro</ce:italic> and <ce:italic>in vivo</ce:italic>, with some having advanced to clinical evaluation against T2DM, non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma. In this review, we describe the structure, mechanism of activation, and biological functions of TBK1, and summarize the small-molecule inhibitors of TBK1 with potential for the treatment of human disease.</ce:para>
               <ce:section id="s0005" view="all">
                  <ce:section-title id="st020">Structure and mechanism of activation of TBK1</ce:section-title>
                  <ce:para id="p0030" view="all">Human TBK1 kinase comprises 745 amino acids, including an N-terminal kinase domain (KD), a ubiquitin-like domain (ULD), an Î±-helical scaffold dimerization domain (SDD), and a C-terminal adaptor-binding domain (CTD) (<ce:cross-ref id="c0075" refid="f0005">Fig. 1</ce:cross-ref>
                     <ce:float-anchor refid="f0005"/></ce:float-anchor>a).<ce:cross-ref id="c0080" refid="b0075">
                        <ce:sup loc="post">15</ce:sup>
                     </ce:cross-ref> The extensive interactions between KD, ULD, and SDD form a compact TBK1 dimer. The KD of TBK1 comprises N- and C-terminal lobes with an active ATP-binding site at the interface. Ser172 on the activation loop is the phosphorylation site of TBK1 kinase.<ce:cross-ref id="c0085" refid="b0080">
                        <ce:sup loc="post">16</ce:sup>
                     </ce:cross-ref> Once TBK1 is phosphorylated, the Î±C-helix of the kinase domain rotates to the inward active position, promoting the formation of a key salt bridge interaction between the conserved Glu55 residue of the Î±C-helix and the active site Lys38 residue. In addition, the activation loop reassembles into an ordered state, which helps the interactions between p-Ser172 and Arg54, Arg134, and Arg162 to stabilize the active conformation of the kinase. However, when TBK1 is in an inactive conformation, the activation loop is disordered and the Î±C-helix is oriented to an inactive position outside the ATP-binding domain (<ce:cross-ref id="c0090" refid="f0005">Fig. 1</ce:cross-ref>b).<ce:cross-ref id="c0095" refid="b0075">
                        <ce:sup loc="post">15</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
                  <ce:para id="p0035" view="all">In the structure of the TBK1 dimer, the two KDs are in a back-to-back position, which limits the <ce:italic>cis</ce:italic>-autophosphorylation activation of TBK1. Indeed, studies have shown that TBK1 activation is mainly controlled by <ce:italic>trans</ce:italic>-autophosphorylation.<ce:cross-ref id="c0100" refid="b0085">
                        <ce:sup loc="post">17</ce:sup>
                     </ce:cross-ref> Upstream stimulation can recruit TBK1 to a specific signaling complex, resulting in local aggregation of TBK1, which creates favorable conditions for two adjacent TBK1 dimers to interact with each other. This interaction can bring the activation loop of the KD close to the catalytic cleft of the KD of another TBK1 dimer. Once Ser172 on the activation loop is phosphorylated, the remaining unphosphorylated TBK1 is quickly activated (<ce:cross-ref id="c0105" refid="f0005">Fig. 1</ce:cross-ref>c).<ce:cross-ref id="c0110" refid="b0090">
                        <ce:sup loc="post">18</ce:sup>
                     </ce:cross-ref> Previous studies have revealed that glycogen synthase kinase 3Î² (GSK3Î²) is recruited to TBK1 after viral infection, promoting autophosphorylation at Ser172 of TBK1, and then promoting an antiviral response.<ce:cross-ref id="c0115" refid="b0095">
                        <ce:sup loc="post">19</ce:sup>
                     </ce:cross-ref> Moreover, Raf kinase inhibitory protein (RKIP) can be phosphorylated at Ser109 by TBK1. Phosphorylation of RKIP enhances its interaction with TBK1 and, in turn, promotes TBK1 autophosphorylation, which is essential for TBK1 activation and type I interferon (IFN) production triggered by viral infection.<ce:cross-ref id="c0120" refid="b0100">
                        <ce:sup loc="post">20</ce:sup>
                     </ce:cross-ref> Li <ce:italic>et al.</ce:italic> showed that Src tyrosine kinase is a major kinase upstream of TBK1 that regulates the tyrosine phosphorylation of TBK1 at Tyr179, which is followed by the autophosphorylation of TBK1 at Ser172.<ce:cross-ref id="c0125" refid="b0105">
                        <ce:sup loc="post">21</ce:sup>
                     </ce:cross-ref> Another study showed that TBK1 Ser172 can be directly phosphorylated by upstream Unc-51-like autophagy-activating kinase 1 (ULK1) in mouse adipocytes, which is important for regulating energy homeostasis.<ce:cross-ref id="c0130" refid="b0110">
                        <ce:sup loc="post">22</ce:sup>
                     </ce:cross-ref> In general, the detailed mechanism of how TBK1 is activated by upstream signaling partners is poorly understood and more research is needed to clarify fully the precise mechanism of TBK1 activation.</ce:para>
               </ce:section>
               <ce:section id="s0010" view="all">
                  <ce:section-title id="st025">Biological functions of TBK1</ce:section-title>
                  <ce:section id="s0015" view="all">
                     <ce:section-title id="st030">TBK1 in innate immunity</ce:section-title>
                     <ce:para id="p0040" view="all">The innate immune system immediately resists infection and mediates the induction of inflammation by recognizing pathogen-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS) (a component of the outer membrane of Gram-negative bacteria) and viral double-stranded (ds) RNA or DNA.<ce:cross-ref id="c0135" refid="b0115">
                           <ce:sup loc="post">23</ce:sup>
                        </ce:cross-ref> Innate immune cells express multiple pattern recognition receptors (PRRs), such as Toll-like receptors (TLRs), RIG-1-like receptors (RLRs), and cytoplasmic DNA sensors, which can recognize different PAMPs and trigger the production of antibodies and inflammatory mediators.<ce:cross-ref id="c0140" refid="b0120">
                           <ce:sup loc="post">24</ce:sup>
                        </ce:cross-ref> In the innate immune system, TBK1 mediates the induction of type I IFN (IFN-Î±/Î²) and antiviral innate immunity in a TLR-dependent manner. The combination of viral dsRNA and TLR3 recruits the adaptors TIR-domain-containing adaptor-inducing IFN-Î² (TRIF) and tumor necrosis factor receptor-associated factor 3 (TRAF3), and finally activates TBK1, which forms a complex with NF-ÎºB-activating kinase-associated protein 1 (NAP1) and IKKÎµ. Activated TBK1 phosphorylates IFN-regulatory factor 3 (IRF3), causing its homodimerization and translocation to the nucleus, thereby driving the expression of antiviral type I IFN.<ce:cross-refs id="r0035" refid="b0125 b0130">
                           <ce:sup loc="post">25,26</ce:sup>
                        </ce:cross-refs> When cells sense the invading pathogen LPS, they can also mediate IRF3 phosphorylation in a TLR4-dependent manner, thereby inducing the release of type I IFN; however, this mechanism of activation also requires the adaptor protein TRIF-related adaptor molecule (TRAM) (<ce:cross-ref id="c0145" refid="f0010">Fig. 2</ce:cross-ref>
                        <ce:float-anchor refid="f0010"/></ce:float-anchor>).</ce:para>
                     <ce:para id="p0045" view="all">In addition to TLRs, cytoplasmic RIG-1-like receptors (RLRs) activated by viral RNA can also activate downstream TBK1, which in turn induces IRF3 activation, and in some cases can also induce IRF7 activation and type I IFN secretion. This requires the interaction of RLRs with the mitochondrial antiviral signaling protein (MAVS), thereby recruiting TRAF3 and/or TRAF6 to the MAVS and causing TBK1 activation. In addition, the detection of DNA in the cytoplasm by a cytoplasmic DNA sensor is a key innate immunity mechanism protecting against various bacterial and viral pathogens.<ce:cross-ref id="c0150" refid="b0135">
                           <ce:sup loc="post">27</ce:sup>
                        </ce:cross-ref> The stimulator of the IFN gene (STING) acts as an adaptor of cytoplasmic DNA sensors, such as cGAS, which activates STING via the synthesis of the secondary messenger, cyclic GMP-AMP (cGAMP). cGAMP induces oligomerization of STING, leading to TBK1 clustering and <ce:italic>trans</ce:italic>-autophosphorylation. Activated TBK1 phosphorylates STING at the C-terminal tail and activated STING can recruit IRF3, which is phosphorylated by TBK1.<ce:cross-ref id="c0155" refid="b0140">
                           <ce:sup loc="post">28</ce:sup>
                        </ce:cross-ref> STING can also be activated after sensing bacterial c-di-AMP and c-di-GMP. Phosphorylated IRF3 forms a dimer that translocates to the nucleus to promote the transcription of IFN genes, leading to the induction of type I IFN and proinflammatory cytokines (<ce:cross-ref id="c0160" refid="f0010">Fig. 2</ce:cross-ref>).<ce:cross-ref id="c0165" refid="b0145">
                           <ce:sup loc="post">29</ce:sup>
                        </ce:cross-ref> Although TBK1 and IKKÎµ have many similar functions, Hemmi <ce:italic>et al.</ce:italic> showed that TBK1 has an irreplaceable role in regulating the induction of IFN-Î², whereas IKKÎµ does not. Impaired induction of IFN-Î² is observed in TLR/RLR-induced TBK1-deficient embryonic fibroblasts, but not IKKÎµ-deficient embryonic fibroblasts.<ce:cross-ref id="c0170" refid="b0150">
                           <ce:sup loc="post">30</ce:sup>
                        </ce:cross-ref> TBK1 kinase is a commonly expressed serine-threonine kinase, which is recognized for its key role in innate immunity. These innate immune signals are essential for establishing an immediate antiviral state during acute infection. By contrast, the chronic activation of these innate immune signals can be detrimental to the host and cause autoimmune diseases. Therefore TBK1 is considered as a potential target for the treatment of inflammatory and autoimmune diseases.<ce:cross-refs id="r0040" refid="b0030 b0035">
                           <ce:sup loc="post">6,7</ce:sup>
                        </ce:cross-refs>
                     </ce:para>
                  </ce:section>
                  <ce:section id="s0020" view="all">
                     <ce:section-title id="st035">TBK1 in human cancer</ce:section-title>
                     <ce:para id="p0050" view="all">Besides its important role in the innate immune response, increasing studies have found that abnormal activation of TBK1 kinase is closely related to the development of cancer, especially cancers with high frequency oncogenic Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) mutations, such as lung cancer, pancreatic cancer, and colorectal cancer. Chien <ce:italic>et al.</ce:italic> discovered that the Ras-like small G-protein/exocyst complex component 2 (RalB-Sec5) complex directly recruits and activates the TBK1 kinase signaling pathway, which establishes a link between TBK1 in innate immunity and cancer signaling.<ce:cross-ref id="c0175" refid="b0155">
                           <ce:sup loc="post">31</ce:sup>
                        </ce:cross-ref> This signaling pathway can inhibit cancer cell apoptosis and, in nontumor cells, stimulate the innate immune response. In a key systematic RNAi experiment, TBK1 was identified as the synthetic lethal partner of oncogenic KRAS.<ce:cross-ref id="c0180" refid="b0050">
                           <ce:sup loc="post">10</ce:sup>
                        </ce:cross-ref> RalB-mediated activation of TBK1 can maintain the viability of KRAS-dependent lung cancer cells. These initial meaningful discoveries led researchers to explore TBK1 inhibition as a potential strategy for treating KRAS mutant cancers.</ce:para>
                     <ce:para id="p0055" view="all">Kim <ce:italic>et al.</ce:italic> showed that TBK1 is involved in the regulation of mitosis by mediating Polo-like kinase 1 (PLK1) phosphorylation, which is essential for maintaining the survival of KRAS-dependent non-small cell lung cancer (NSCLC) cells.<ce:cross-ref id="c0185" refid="b0160">
                           <ce:sup loc="post">32</ce:sup>
                        </ce:cross-ref> Another study showed that TBK1 regulates microtubule dynamics and mitosis by binding and phosphorylating centrosome protein CEP170 and mitotic protein NuMA.<ce:cross-ref id="c0190" refid="b0165">
                           <ce:sup loc="post">33</ce:sup>
                        </ce:cross-ref> The important role of TBK1 in the regulation of mitosis has provided further evidence for the potential of targeting TBK1 to treat cancer, especially KRAS mutation-dependent disease. Zhu <ce:italic>et al.</ce:italic> provided insights into how RalB-TBK1 drives KRAS-induced lung cancer.<ce:cross-ref id="c0195" refid="b0170">
                           <ce:sup loc="post">34</ce:sup>
                        </ce:cross-ref> Carcinogenic KRAS-RalB signaling can activate TBK1/IKKÎµ and induce the secretion of interleukin (IL)-6 and chemokine ligand 5 (CCL5). These cytokines can activate Janus kinase/signal transduction and activation of transcription (JAK/STAT) signaling in an autocrine manner and induce IKKÎµ expression, thereby triggering further CCL5 and IL-6 production. Therefore, cytokine-activated lung cancer cell proliferation and migration can be maintained (<ce:cross-ref id="c0200" refid="f0015">Fig. 3</ce:cross-ref>
                        <ce:float-anchor refid="f0015"/></ce:float-anchor>). The multi-targeted JAK/TBK1/IKKÎµ inhibitor CYT387 (momelotinib; discussed further later) can disrupt this autocrine cytokine circuit, thereby inducing the regression of lung tumors in a murine model of KRAS G12D-driven lung cancer. Based on these research results, it was found that the subsequent use of CYT387 in combination with mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor AZD6244 results in statistically significant tumor regression in murine KRAS<ce:sup loc="post">LSL-G12D/WT</ce:sup>; p53<ce:sup loc="post">flflox/flflox</ce:sup> (KP) lung cancer, which is a treatment-refractory lung cancer model. However, because of the development of acquired resistance through alternative pathway activation, this dual therapy fails to achieve a durable response. Kitajima <ce:italic>et al.</ce:italic> found that intermittent treatment with the bromodomain and extra-terminal domain (BET) inhibitor JQ1 can overcome drug resistance in this dual-therapy approach, providing a prolonged treatment effect in the murine KP lung cancer model.<ce:cross-ref id="c0205" refid="b0175">
                           <ce:sup loc="post">35</ce:sup>
                        </ce:cross-ref>
                     </ce:para>
                     <ce:para id="p0060" view="all">In addition to being expressed in KRAS-dependent lung cancer, TBK1 is abundantly expressed in KRAS-mutant pancreatic ductal adenocarcinoma (PDAC). Notably, the high mortality rate of PDAC is closely related to tumor metastasis.<ce:cross-ref id="c0210" refid="b0180">
                           <ce:sup loc="post">36</ce:sup>
                        </ce:cross-ref> Studies have shown that the receptor tyrosine kinase AXL activates TBK1 in a RAS-RalB-dependent manner, thereby promoting an increase in pancreatic cancer cell epithelial-mesenchymal transition (EMT) and making tumor cells more invasive and metastatic (<ce:cross-ref id="c0215" refid="f0015">Fig. 3</ce:cross-ref>).<ce:cross-ref id="c0220" refid="b0185">
                           <ce:sup loc="post">37</ce:sup>
                        </ce:cross-ref> Compared with wild-type TBK1 PDAC mice, PDAC mice lacking kinase-active TBK1 have significantly smaller epithelial tumors and fewer metastatic lesions.</ce:para>
                     <ce:para id="p0065" view="all">However, the synthetic lethal relationship between oncogenic KRAS and TBK1 kinase remains controversial. Studies have found that TBK1 inhibitors and some short-hairpin RNAs (shRNAs) targeting TBK1 can effectively reduce the activity of TBK1 in some tumor cell lines expressing oncogenic KRAS (such as NSCLC and PDAC cell lines), but there is no clear evidence that TBK1 is essential in regulating the growth and proliferation of these cancer cell lines.<ce:cross-refs id="r0045" refid="b0190 b0195">
                           <ce:sup loc="post">38,39</ce:sup>
                        </ce:cross-refs> For example, Muvaffak <ce:italic>et al.</ce:italic> found that, in two NSCLC cell lines (H23 and A549) with KRAS mutations, six different shRNAs all showed significant downregulation of TBK1 protein. However, knockdown of TBK1 did not lead to a decrease in the viability of these cell lines. In general, more research is needed to elucidate the mechanism of TBK1 in the proliferation and growth of cancer. TBK1 inhibition alone is not sufficient to produce strong inhibition of cancer cell growth. The combination with KRAS pathway inhibitors might be a promising strategy for the treatment of KRAS-mutant tumors.</ce:para>
                     <ce:para id="p0070" view="all">In addition, recent research has shown that TBK1 is a synthetic lethal target in cancer with VHL loss.<ce:cross-ref id="c0225" refid="b0200">
                           <ce:sup loc="post">40</ce:sup>
                        </ce:cross-ref> VHL mutations are found in most kidney cancers, and the loss of VHL function is crucial to renal carcinogenesis.<ce:cross-ref id="c0230" refid="b0205">
                           <ce:sup loc="post">41</ce:sup>
                        </ce:cross-ref> In kidney cancer cell lines, loss of VHL can lead to hyperactivation of TBK1, which promotes the phosphorylation of its downstream partner p62 at Ser366 to stabilize the p62 protein. Knock down of TBK1 (but not its homolog IKKÎµ) or pharmacological inhibition of TBK1 can specifically inhibit the growth of VHL-deficient renal cancer cells, whereas wild-type VHL cells are unaffected.<ce:cross-ref id="c0235" refid="b0200">
                           <ce:sup loc="post">40</ce:sup>
                        </ce:cross-ref> Therefore, future in-depth research on the synthetic lethal relationship between TBK1 and VHL loss is expected to provide potential opportunities for the treatment of cancers with VHL loss.</ce:para>
                  </ce:section>
                  <ce:section id="s0025" view="all">
                     <ce:section-title id="st040">TBK1 in autophagy</ce:section-title>
                     <ce:para id="p0075" view="all">Autophagy is a self-digestion process in which cells degrade various components, including the digestion of damaged or excessive proteins and organelles.<ce:cross-ref id="c0240" refid="b0210">
                           <ce:sup loc="post">42</ce:sup>
                        </ce:cross-ref> The disorder of autophagy can also cause diseases, such as cancer and neurodegenerative diseases.<ce:cross-refs id="r0050" refid="b0215 b0220">
                           <ce:sup loc="post">43,44</ce:sup>
                        </ce:cross-refs> Although autophagy is traditionally considered to be a nonselective process, there is growing evidence that autophagy receptors can link ubiquitinated autophagy substrates to autophagosomes, resulting in damaged organelles or invading pathogens being selectively degraded.<ce:cross-ref id="c0245" refid="b0225">
                           <ce:sup loc="post">45</ce:sup>
                        </ce:cross-ref>
                     </ce:para>
                     <ce:para id="p0080" view="all">TBK1 can participate in the selective autophagy pathway to eliminate cytoplasmic invasive bacteria or damaged mitochondria. Wild <ce:italic>et al.</ce:italic> showed that TBK1 kinase can recruit the autophagy receptor optineurin (OPTN) to ubiquitinate cytoplasmic salmonella and phosphorylate the OPTN receptor, which promotes the elimination of cytoplasmic salmonella.<ce:cross-ref id="c0250" refid="b0025">
                           <ce:sup loc="post">5</ce:sup>
                        </ce:cross-ref> Studies also showed that TBK1 is responsible for maintaining IL-1Î² activity and promoting the maturation of autophagosomes to eliminate mycobacteria in macrophages.<ce:cross-ref id="c0255" refid="b0230">
                           <ce:sup loc="post">46</ce:sup>
                        </ce:cross-ref> TBK1 can also control the selective autophagy of damaged mitochondria through phosphorylated autophagy receptors, including sequestosome 1 (p62) and OPTN. Furthermore, TBK1 mutations can affect the phosphorylation of autophagy receptors (such as OPTN and p62), resulting in impaired selective autophagy pathways in protein aggregates or damaged mitochondria.<ce:cross-refs id="r0055" refid="b0235 b0240">
                           <ce:sup loc="post">47,48</ce:sup>
                        </ce:cross-refs> This contributes to the progression of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), which is characterized by the accumulation of misfolded proteins in cytoplasmic inclusions and mitochondrial vacuolation.<ce:cross-ref id="c0260" refid="b0245">
                           <ce:sup loc="post">49</ce:sup>
                        </ce:cross-ref>
                     </ce:para>
                     <ce:para id="p0085" view="all">The earlier discussion clarifies the role of TBK1 in mediating the selective autophagy of pathogens and damaged mitochondria. One of the characteristics of PDAC is the upregulation of autophagy, with inhibition of autophagy leading to significant regression of a mouse model of PDAC.<ce:cross-refs id="r0060" refid="b0250 b0255">
                           <ce:sup loc="post">50,51</ce:sup>
                        </ce:cross-refs> Yang <ce:italic>et al.</ce:italic> linked TBK1-mediated autophagy to PDAC.<ce:cross-ref id="c0265" refid="b0055">
                           <ce:sup loc="post">11</ce:sup>
                        </ce:cross-ref> Inhibition of autophagy <ce:italic>in vitro</ce:italic> in PDAC cells caused excessive activation of TBK1 protein that induced the upregulation of proinflammatory cytokines CCL5 and IL-6. There is also a negative feedback mechanism between TBK1 and autophagy. TBK1 can promote basic autophagy required by PDAC cells, subsequently leading to autophagy-mediated degradation of pTBK1, thereby preventing excessive activation of TBK1 and the accompanying production of cytokines that can promote cancer development (such as CCL5 and IL-6) (<ce:cross-ref id="c0270" refid="f0015">Fig. 3</ce:cross-ref>). In PDAC cell lines and mouse models with high basal autophagy, CYT387 both inhibits basal autophagy and weakens the production of cytokines, thereby limiting abnormal pancreatic development. This finding suggests the future utility of inhibition of TBK1-mediated autophagy in the treatment of PDAC.</ce:para>
                  </ce:section>
                  <ce:section id="s0030" view="all">
                     <ce:section-title id="st045">TBK1 in antitumor immunity</ce:section-title>
                     <ce:para id="p0090" view="all">In the earlier discussion, we summarized the role of TBK1 kinase in mediating innate immunity. Xiao <ce:italic>et al.</ce:italic> clarified the potential effect of antitumor immunity by targeting TBK1 in dendritic cells (DCs).<ce:cross-ref id="c0275" refid="b0060">
                           <ce:sup loc="post">12</ce:sup>
                        </ce:cross-ref> DCs are essential for maintaining T cell homeostasis and immune tolerance of self-antigens, which not only helps prevent autoimmune diseases, but also hinders the immune response against cancer.<ce:cross-ref id="c0280" refid="b0260">
                           <ce:sup loc="post">52</ce:sup>
                        </ce:cross-ref> Therefore, breaking this immune tolerance can promote antitumor immunity. TBK1 is essential for maintaining the above-mentioned functions of DCs. The specific loss of TBK1 in DCs leads to abnormal activation of T cells and autoimmune symptoms, including splenomegaly, lymphadenopathy, and lymphocyte infiltration. In the B16 melanoma mouse model, the specific deletion of TBK1 in DCs (TBK1-DKO) resulted in a substantial reduction in tumor growth, significantly increasing the survival rate of tumor-bearing mice. In addition, the combination of programmed death receptor-1 (PD1) blockade and TBK1 deletion showed a powerful synergistic effect. A corresponding study in a mouse model bearing CT26 colorectal tumors demonstrated that the combination of antiprogrammed death ligand 1 (PD-L1) and TBK1 inhibitors resulted in improved tumor control and prolonged survival compared with the use of either agent alone.<ce:cross-ref id="c0285" refid="b0265">
                           <ce:sup loc="post">53</ce:sup>
                        </ce:cross-ref> A recent study also confirmed the antitumor immunity potential of TBK1. Knockout of TBK1, or pharmacological inhibition with amlexanox (discussed further later), can attenuate tumor growth and enhance antitumor immunity, which manifests as the significantly increased frequency of CD4<ce:sup loc="post">+</ce:sup> and CD8<ce:sup loc="post">+</ce:sup> effector T cells (<ce:cross-ref id="c0290" refid="f0015">Fig. 3</ce:cross-ref>).<ce:cross-ref id="c0295" refid="b0270">
                           <ce:sup loc="post">54</ce:sup>
                        </ce:cross-ref> In conclusion, these results suggest that targeting TBK1 holds significant promise to improve the effect of cancer immunotherapy.</ce:para>
                  </ce:section>
                  <ce:section id="s0035" view="all">
                     <ce:section-title id="st050">TBK1 in metabolic diseases</ce:section-title>
                     <ce:para id="p0095" view="all">A high-fat diet (HFD) and TNFÎ± expression caused by obesity activates NF-ÎºB in adipocytes, inducing the expression of TBK1 and IKKÎµ.<ce:cross-ref id="c0300" refid="b0275">
                           <ce:sup loc="post">55</ce:sup>
                        </ce:cross-ref> In the obese state, phosphorylation of IKKÎµ and TBK1 activates phosphodiesterase 3B (PDE3B) to decrease the sensitivity of cAMP to catecholamines (such as epinephrine), which prevents catecholamines from inducing uncoupling protein 1 (UCP1) expression.<ce:cross-ref id="c0305" refid="b0280">
                           <ce:sup loc="post">56</ce:sup>
                        </ce:cross-ref> In particular, NF-ÎºB induces TBK1 to directly inhibit AMP-activated protein kinase (AMPK) to restrain the expression of UCP1.<ce:cross-ref id="c0310" refid="b0110">
                           <ce:sup loc="post">22</ce:sup>
                        </ce:cross-ref> Therefore, IKKÎµ and TBK1 mediate downstream pathways to indirectly prevent UCP1-mediated oxidative phosphorylation during mitochondrial respiration to inhibit respiration, regulate fat production and reduce energy consumption. In addition, IKKÎµ and TBK1 affect the activity of hormone-sensitive lipase by inhibiting the PDE3B-cAMP-PKA pathway, thereby reducing lipolysis and causing an imbalance in energy homeostasis (<ce:cross-ref id="c0315" refid="f0020">Fig. 4</ce:cross-ref>
                        <ce:float-anchor refid="f0020"/></ce:float-anchor>a).<ce:cross-ref id="c0320" refid="b0285">
                           <ce:sup loc="post">57</ce:sup>
                        </ce:cross-ref> Although knocking out TBK1 in fat cells alleviated the symptoms of obesity, it also affected the negative feedback regulation of NF-ÎºB, leading to inflammation. Amlexanox can inhibit effectively the activity of TBK1 and IKKÎµ, increase the sensitivity of catecholamines in adipose tissue to achieve weight loss, and reduce inflammation of adipose tissue caused by insulin resistance.<ce:cross-ref id="c0325" refid="b0290">
                           <ce:sup loc="post">58</ce:sup>
                        </ce:cross-ref>
                     </ce:para>
                     <ce:para id="p0100" view="all">Diabetes is a metabolic disease in which Î² cell failure and decreased insulin sensitivity lead to decreased insulin secretion or decreased insulin action, resulting in increased blood glucose.<ce:cross-ref id="c0330" refid="b0295">
                           <ce:sup loc="post">59</ce:sup>
                        </ce:cross-ref> Recent studies revealed the role of TBK1 in regulating Î² cell regeneration and insulin resistance. Xu <ce:italic>et al.</ce:italic> discovered the cAMP-PKA-mTOR signaling pathway in Î² cells, which affects Î² cell replication and regeneration mediated by TBK1. In Î² cells, the activation of TBK1 and IKKÎµ increases the activity of PDE3B, which inhibits the expression of cAMP and, therefore, reduces the activity of cAMP-dependent protein kinase A (PKA), blocking the phosphorylation of mammalian target of rapamycin (mTOR). Therefore, mTOR-mediated Î² cell replication and regeneration is inhibited (<ce:cross-ref id="c0335" refid="f0020">Fig. 4</ce:cross-ref>b).<ce:cross-ref id="c0340" refid="b0070">
                           <ce:sup loc="post">14</ce:sup>
                        </ce:cross-ref> In addition, Munoz <ce:italic>et al.</ce:italic> found that TBK1 promotes the phosphorylation of the insulin receptor at Ser994, negatively regulating insulin signaling and reducing insulin sensitivity.<ce:cross-ref id="c0345" refid="b0300">
                           <ce:sup loc="post">60</ce:sup>
                        </ce:cross-ref>
                     </ce:para>
                     <ce:para id="p0105" view="all">Nonalcoholic fatty liver disease (NAFLD) usually co-occurs with obesity and T2DM. A recent study found that, under obesity, TBK1 phosphorylated by upstream signals displays reduced binding with acyl-CoA synthetase long-chain family member 1 (ACSL1), which is the rate-limiting enzyme of fatty acid oxidation. TBK1 locates ASCSL1 in the endoplasmic reticulum, which has a role in increasing the re-esterification of fatty acids and promoting the accumulation of lipid substances.<ce:cross-ref id="c0350" refid="b0305">
                           <ce:sup loc="post">61</ce:sup>
                        </ce:cross-ref> He <ce:italic>et al.</ce:italic> demonstrated that, in hepatic stellate cells (HSCs) of NAFLD induced by HFDÂ +Â LPS, TBK1 inhibition by amlexanox can attenuate hepatic steatosis and maintain the homeostasis of glucose and lipid metabolism in the liver.<ce:cross-ref id="c0355" refid="b0310">
                           <ce:sup loc="post">62</ce:sup>
                        </ce:cross-ref> These studies indicate that TBK1 is a potential target for metabolic diseases, such as obesity, diabetes, and NAFLD. Thus, inhibition of the TBK1 signaling pathway is expected to become a new strategy for metabolic diseases.</ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="s0040" view="all">
                  <ce:section-title id="st055">Small-molecule inhibitors of TBK1</ce:section-title>
                  <ce:para id="p0110" view="all">An in-depth understanding of the structural biology of TBK1 provides the possibility for the development of small-molecule inhibitors as therapeutic agents. Currently known TBK1 inhibitors in development include aminopyrimidines, amlexanox and its derivatives, imidazopyridines, and benzimidazoles and their analogs. Most of these inhibitors show good biochemical TBK1 inhibition, and inhibition of disease development at the level of cellular or animal models, such as cancer, metabolic diseases, inflammatory, and autoimmune diseases. For example, clinical trials verified the effect of the TBK1 inhibitor amlexanox on blood glucose control in patients with T2DM and CYT387 (momelotinib) in KRAS mutation-dependent NSCLC and PDAC. However, the development of TBK1 inhibitors still has problems, such as improving target potency and selectivity, physical and chemical properties, pharmacokinetics, and toxicity. There is still an urgent need to develop further TBK1 inhibitors based on new chemical scaffolds. Here, we focus mainly on the most recent advances in the discovery of novel TBK1 inhibitors.</ce:para>
                  <ce:section id="s0045" view="all">
                     <ce:section-title id="st060">Amlexanox</ce:section-title>
                     <ce:para id="p0115" view="all">Amlexanox (<ce:bold>1</ce:bold>) is an approved drug for the treatment of aphthous ulcers and asthma (<ce:cross-ref id="c0360" refid="f0025">Fig. 5</ce:cross-ref>
                        <ce:float-anchor refid="f0025"/></ce:float-anchor>a). It is also an inhibitor of IKKÎµ and TBK1 with IC<ce:inf loc="post">50</ce:inf> value of 5.8Â Î¼M and 0.8Â Î¼M, respectively.<ce:cross-ref id="c0365" refid="b0315">
                           <ce:sup loc="post">63</ce:sup>
                        </ce:cross-ref> An X-ray crystal structure of TBK1 with amlexanox shows that it binds to the ATP-binding site of TBK1 with a type I binding mode (<ce:cross-ref id="c0370" refid="f0030">Fig. 6</ce:cross-ref>
                        <ce:float-anchor refid="f0030"/></ce:float-anchor>a). The pyridine nitrogen and amine form hydrogen bonds with Glu87 and Cys89, respectively, being largely responsible for the potency of TBK1 inhibition. The carboxylic acid is proposed to form a weak hydrogen bond or favorable electrostatic interactions with Thr156 by virtue of the 4.1Â Ã distance between them.<ce:cross-ref id="c0375" refid="b0315">
                           <ce:sup loc="post">63</ce:sup>
                        </ce:cross-ref> Biological studies indicated that amlexanox elevates energy expenditure by increasing thermogenesis, improving insulin sensitivity, and decreasing weight and steatosis in mice.<ce:cross-refs id="r0065" refid="b0290 b0320">
                           <ce:sup loc="post">58,64</ce:sup>
                        </ce:cross-refs> Similarly, in clinical trials in patients with T2DM, amlexanox reduced blood glucose levels, improved insulin sensitivity, increased energy expenditure gene expression, and decreased glycated hemoglobin (HbA1c) in some patients.<ce:cross-ref id="c0380" refid="b0320">
                           <ce:sup loc="post">64</ce:sup>
                        </ce:cross-ref> Therefore, it has been suggested that amlexanox could be redeveloped as an antidiabetes and antiobesity agent. In addition, it has also been reported that amlexanox can reduce liver fibrosis and acute liver injury caused by acetaminophen in mice through inhibition of TBK1/IKKÎµ.<ce:cross-refs id="r0070" refid="b0325 b0330">
                           <ce:sup loc="post">65,66</ce:sup>
                        </ce:cross-refs>
                     </ce:para>
                     <ce:para id="p0120" view="all">However, the low solubility and moderate efficacy of amlexanox have limited its further development. Beyett <ce:italic>et al.</ce:italic> investigated modifications of the C3-carboxylic acid and C7-isopropyl substituent of amlexanox. Among the analogs, only compound <ce:bold>2</ce:bold> with a tetrazole carboxylic acid bio-isostere demonstrated improved potency for biochemical inhibition of TBK1 and IKKÎµ, with IC<ce:inf loc="post">50</ce:inf> values of 400 and 200Â nM, respectively; however, cellular potency for this compound was low. Of the other analogs described, the C7-cyclohexyl analog <ce:bold>3</ce:bold> produced the highest levels of IL-6 secretion in 3Â T3-L1 cells, which is a biomarker of the potency of TBK1/IKKÎµ inhibition. Unfortunately, the combination of the C3-tetrazole and C7-cyclohexyl group, as for compound <ce:bold>4</ce:bold>, did not achieve a synergistic effect (<ce:cross-ref id="c0385" refid="f0025">Fig. 5</ce:cross-ref>a).<ce:cross-refs id="r0075" refid="b0315 b0335">
                           <ce:sup loc="post">63,67</ce:sup>
                        </ce:cross-refs>
                     </ce:para>
                  </ce:section>
                  <ce:section id="s0050" view="all">
                     <ce:section-title id="st065">Aminopyrimidines</ce:section-title>
                     <ce:para id="p0125" view="all">A PDK1 kinase inhibitor BX795 (<ce:bold>5</ce:bold>) (<ce:cross-ref id="c0390" refid="f0025">Fig. 5</ce:cross-ref>b) has been identified as a potent TBK1 inhibitor with a biochemical IC<ce:inf loc="post">50</ce:inf> of 2.3Â nM.<ce:cross-ref id="c0395" refid="b0340">
                           <ce:sup loc="post">68</ce:sup>
                        </ce:cross-ref> An X-ray crystal structure of TBK1 with BX795 shows that it binds in a type I binding mode (<ce:cross-ref id="c0400" refid="f0030">Fig. 6</ce:cross-ref>b).<ce:cross-ref id="c0405" refid="b0345">
                           <ce:sup loc="post">69</ce:sup>
                        </ce:cross-ref> Briefly, the aminopyrimidine donor/acceptor motif forms two hydrogen bonds with Cys89. The carbonyl group of the thiophene carboxamide forms a hydrogen bond with Lys38, whereas the urea carbonyl forms hydrogen bonds with Ser93 and Thr96, thus fixing its binding conformation (<ce:cross-ref id="c0410" refid="f0030">Fig. 6</ce:cross-ref>b).<ce:cross-ref id="c0415" refid="b0080">
                           <ce:sup loc="post">16</ce:sup>
                        </ce:cross-ref> Biological assays showed that BX795 can inhibit the inflammatory response caused by Gram-positive bacteria and the infection caused by a variety of drug-resistant herpes simplex virus type 1 (HSV-1) strain cells.<ce:cross-refs id="r0080" refid="b0350 b0355">
                           <ce:sup loc="post">70,71</ce:sup>
                        </ce:cross-refs> In addition, BX795 showed an inhibitory effect on the proliferation of oral squamous cell carcinoma (OSCC) by inducing apoptosis and Mâphase arrest.<ce:cross-ref id="c0420" refid="b0360">
                           <ce:sup loc="post">72</ce:sup>
                        </ce:cross-ref> Similarly, BX795 can effectively attenuate the proliferation and migration of bladder cancer cells and PDAC cells <ce:italic>in vitro</ce:italic>. This effect was also confirmed in an <ce:italic>in vivo</ce:italic> mouse model of xenotransplantation.<ce:cross-refs id="r0085" refid="b0365 b0370">
                           <ce:sup loc="post">73,74</ce:sup>
                        </ce:cross-refs> In short, BX795 is expected to be developed as a broad-spectrum inhibitor for the treatment of various cancers and inflammation caused by bacterial or viral infections. However, the off-target effects of BX795 on other kinases might limit its further development. Further optimization of BX795 led to MRT67307 (<ce:bold>6</ce:bold>) (<ce:cross-ref id="c0425" refid="f0025">Fig. 5</ce:cross-ref>b), which demonstrated good selectivity against IKKÎ±, IKKÎ², JNK, and p38 MAPK.<ce:cross-ref id="c0430" refid="b0375">
                           <ce:sup loc="post">75</ce:sup>
                        </ce:cross-ref> MRT67307 inhibits TBK1 and IKKÎµ, with biochemical IC<ce:inf loc="post">50</ce:inf> values of 19Â nM and 160Â nM, respectively. An X-ray crystal structure of TBK1 with MRT67307 shows that it binds with a similar mode to BX795, but forms fewer interactions with the kinase compared with BX795, resulting in reduced potency and fewer off-target effects (<ce:cross-ref id="c0435" refid="f0030">Fig. 6</ce:cross-ref>c).<ce:cross-ref id="c0440" refid="b0080">
                           <ce:sup loc="post">16</ce:sup>
                        </ce:cross-ref>
                     </ce:para>
                     <ce:para id="p0130" view="all">CYT387 (momelotinib) (<ce:bold>7</ce:bold>, <ce:cross-ref id="c0445" refid="f0025">Fig. 5</ce:cross-ref>b), a JAK1/2 kinase inhibitor for the treatment of myelofibrosis, shows potent biochemical inhibitory activity against TBK1 (IC<ce:inf loc="post">50</ce:inf>Â =Â 58Â nM) and IKKÎµ (IC<ce:inf loc="post">50</ce:inf>Â =Â 42Â nM).<ce:cross-refs id="r0090" refid="b0170 b0380">
                           <ce:sup loc="post">34,76</ce:sup>
                        </ce:cross-refs> It can effectively promote tumor regression in animal models of NSCLC and PDAC driven by KRAS mutations based on its inhibition of tumor-dependent cytokines and basic autophagy.<ce:cross-refs id="r0095" refid="b0055 b0170">
                           <ce:sup loc="post">11,34</ce:sup>
                        </ce:cross-refs> CYT387 alone or in combination with other drugs has shown strong antitumor effects in animal models. However, two clinical trials that combined CYT387 with MEK inhibitor trametinib to treat NSCLC and with chemotherapy drugs gemcitabine and Nab-paclitaxel to treat PDAC were terminated (NCT02258607 and NCT02101021),<ce:cross-refs id="r0100" refid="b0385 b0390">
                           <ce:sup loc="post">77,78</ce:sup>
                        </ce:cross-refs> because of a lack of observed therapeutic effects. GSK8612 (<ce:bold>8</ce:bold>) (<ce:cross-ref id="c0450" refid="f0025">Fig. 5</ce:cross-ref>b), is a highly selective TBK1 inhibitor (IC<ce:inf loc="post">50</ce:inf>Â =Â 6.8, p<ce:italic>K</ce:italic>
                        <ce:inf loc="post">d</ce:inf>Â =Â 8.0) that effectively inhibits TBK1-mediated IRF3 phosphorylation and IFNÎ± and IFNÎ² secretion. This agent is expected to be an ideal probe for biological research of TBK1.<ce:cross-ref id="c0455" refid="b0395">
                           <ce:sup loc="post">79</ce:sup>
                        </ce:cross-ref>
                     </ce:para>
                  </ce:section>
                  <ce:section id="s0055" view="all">
                     <ce:section-title id="st070">Others</ce:section-title>
                     <ce:para id="p0135" view="all">AstraZeneca has reported a series of imidazopyridines as TBK1 inhibitors.<ce:cross-refs id="r0105" refid="b0400 b0405">
                           <ce:sup loc="post">80,81</ce:sup>
                        </ce:cross-refs> The representative compound <ce:bold>9</ce:bold> (<ce:cross-ref id="c0460" refid="f0025">Fig. 5</ce:cross-ref>c) inhibits TBK1 with a biochemical IC<ce:inf loc="post">50</ce:inf> value of 9Â nM, has no inhibitory activity against CDK2 and Aurora B kinase, while demonstrating enhanced efficacy and good kinase selectivity. The combination of the structurally similar imidazopyridine derivative AZ3102909 (<ce:bold>10</ce:bold>) (<ce:cross-ref id="c0465" refid="f0025">Fig. 5</ce:cross-ref>c) (TBK1 biochemical IC<ce:inf loc="post">50</ce:inf>Â =Â 5Â nM) and MEK inhibitor AZD6244 synergistically induced apoptosis in drug-resistant NRAS mutant melanoma cells.<ce:cross-ref id="c0470" refid="b0410">
                           <ce:sup loc="post">82</ce:sup>
                        </ce:cross-ref> However, the <ce:italic>in vivo</ce:italic> effects of AZ3102909 need to be further confirmed.</ce:para>
                     <ce:para id="p0140" view="all">Compound II (<ce:bold>11</ce:bold>) with a pyrazolo[3,4-<ce:italic>d</ce:italic>]pyrimidine scaffold is a potent inhibitor of TBK1 (IC<ce:inf loc="post">50</ce:inf>Â =Â 13Â nM) with low toxicity (<ce:cross-ref id="c0475" refid="f0025">Fig. 5</ce:cross-ref>c),<ce:cross-ref id="c0480" refid="b0415">
                           <ce:sup loc="post">83</ce:sup>
                        </ce:cross-ref> and has a good <ce:italic>in vivo</ce:italic> therapeutic effect in autoimmune diseases, such as systemic lupus erythematosus, in mice. In terms of cancer, the inhibitory effect of compound II on TBK1 results in reduced downstream AKT signaling, which in turn has growth inhibitory effects on a variety of cancer cell lines, especially those of a NSCLC origin.<ce:cross-refs id="r0110" refid="b0190 b0415">
                           <ce:sup loc="post">38,83</ce:sup>
                        </ce:cross-refs>
                     </ce:para>
                     <ce:para id="p0145" view="all">BAY985 (<ce:bold>12</ce:bold>) (<ce:cross-ref id="c0485" refid="f0025">Fig. 5</ce:cross-ref>c), with a benzimidazole scaffold, is a selective potent TBK1 inhibitor (biochemical IC<ce:inf loc="post">50</ce:inf>Â =Â 2Â nM) reported by Bayer. Molecular docking indicates that BAY985 binds in a type I mode with the aminoimidazole donor/acceptor motif forming two hydrogen bonds with Cys89. In addition, the carbonyl oxygen and pyrimidine nitrogen form hydrogen bonds with Arg25 and Lys38, respectively (<ce:cross-ref id="c0490" refid="f0030">Fig. 6</ce:cross-ref>d). It is suggested that the rotation of gatekeeper Met86 allows BAY985 to occupy a favorable hydrophobic pocket and avoid spatial conflict with the kinase. However, BAY985 shows poor pharmacokinetic properties in male rats, with high clearance (CL<ce:inf loc="post">b</ce:inf>Â =Â 4.0Â l/h/kg), a large steady-state distribution (VssÂ =Â 2.9Â l/kg), a short terminal half-life (t<ce:inf loc="post">1/2</ce:inf>Â =Â 0.79Â h), and low oral bioavailability (11%), consistent with the weak antitumor activity reported in the SK-MEL-2 human melanoma xenograft in female NMRI nude mice.<ce:cross-ref id="c0495" refid="b0420">
                           <ce:sup loc="post">84</ce:sup>
                        </ce:cross-ref>
                     </ce:para>
                  </ce:section>
               </ce:section>
               <ce:section id="s0060" view="all">
                  <ce:section-title id="st075">Concluding remarks</ce:section-title>
                  <ce:para id="p0150" view="all">With an in-depth understanding of the tertiary structure of TBK1 kinase and its range of biological functions, TBK1 has become a potential target for the treatment of inflammatory diseases, autoimmune diseases, cancer, metabolic diseases, and neurodegenerative diseases. To date, several classes of TBK1 inhibitor based on different chemical scaffolds have been developed. These inhibitors have been investigated for the treatment of inflammatory diseases, metabolic diseases, pancreatic cancer, and NSCLC driven by oncogenic KRAS. However, there is no TBK1 kinase inhibitor approved by the US Food and Drug Administration (FDA) to date. Only CYT387 and amlexanox have undergone clinical evaluation. Amlexanox has demonstrated efficacy in animal models and clinical trials and is considered to be a promising therapeutic candidate for the treatment of obesity, T2DM, or nonalcoholic fatty liver. However, CYT387 was terminated following Phase I clinical trial in patients with mutant-KRAS NSCLC and pancreatic ductal carcinoma because of the limited efficacy observed. Nevertheless, targeting TBK1 to block RalB signaling, downstream of KRAS, remains a potential therapeutic strategy for the treatment of metastatic and refractory NSCLC and pancreatic cancer. Given the high structural similarity, the reported small-molecule inhibitors cannot achieve selective inhibition of the two homologous kinases TBK1 and IKKÎµ. The development of more efficient and specific novel TBK1 inhibitors remains worthy of significant effort. In addition, proteolysis targeting chimera (PROTAC) technology provides a promising new approach for the development of selective TBK1 degraders as chemical probes to explore the specific biological functions of TBK1.<ce:cross-ref id="c0500" refid="b0425">
                        <ce:sup loc="post">85</ce:sup>
                     </ce:cross-ref>
                  </ce:para>
               </ce:section>
            </ce:sections>
            <ce:conflict-of-interest id="coi005" view="all">
               <ce:section-title id="st080">Declaration of Competing Interest</ce:section-title>
               <ce:para id="p0155" view="all">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</ce:para>
            </ce:conflict-of-interest>
            <ce:acknowledgment id="ak005" view="all">
               <ce:section-title id="st085">Acknowledgments</ce:section-title>
               <ce:para id="p0160" view="all">We appreciate the financial support from <ce:grant-sponsor id="gp005" sponsor-id="http://dx.doi.org/10.13039/501100001809" xlink:role="http://www.elsevier.com/xml/linking-roles/grant-sponsor" xlink:type="simple">National Natural Science Foundation of China</ce:grant-sponsor> (<ce:grant-number refid="gp005">81922062</ce:grant-number>), National Key Research and Development Program of China (2018YFE0105800) and the Health Research Council of New Zealand (18/1016).</ce:para>
            </ce:acknowledgment>
         </body>
         <tail view="all">
            <ce:bibliography id="bi005" view="all">
               <ce:section-title id="st090">References</ce:section-title>
               <ce:bibliography-sec id="bs005" view="all">
                  <ce:bib-reference id="b0005">
                     <ce:label>1</ce:label>
                     <sb:reference id="h0005">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.L.</ce:given-name>
                                 <ce:surname>Pomerantz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Baltimore</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>NF-ÎºB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>EMBO J</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>18</sb:volume-nr>
                              </sb:series>
                              <sb:date>1999</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>6694</sb:first-page>
                              <sb:last-page>6704</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx025">Pomerantz JL, Baltimore D. NF-ÎºB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J 1999; 18: 6694â6704.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0010">
                     <ce:label>2</ce:label>
                     <sb:reference id="h0010">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.S.</ce:given-name>
                                 <ce:surname>Yi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.Y.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Oh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Jeong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Cho</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The pivotal role of TBK1 in inflammatory responses mediated by macrophages</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mediators Inflamm</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>2012</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:article-number>979105</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx030">Yu T, Yi YS, Yang YY, Oh J , Jeong D , Cho JY. The pivotal role of TBK1 in inflammatory responses mediated by macrophages. Mediators Inflamm 2012; 2012: 979105.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0015">
                     <ce:label>3</ce:label>
                     <sb:reference id="h0015">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Hammaker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.L.</ce:given-name>
                                 <ce:surname>Boyle</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Firestein</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Synoviocyte innate immune responses: TANK-binding kinase-1 as a potential therapeutic target in rheumatoid arthritis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Rheumatology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>51</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>610</sb:first-page>
                              <sb:last-page>618</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx035">Hammaker D, Boyle DL, Firestein GS. Synoviocyte innate immune responses: TANK-binding kinase-1 as a potential therapeutic target in rheumatoid arthritis. Rheumatology 2012; 51: 610â618.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0020">
                     <ce:label>4</ce:label>
                     <sb:reference id="h0020">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Chau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Gioia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Gatot</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Patrascu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Carpentier</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Chapelle</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Are the IKKs and IKK-related kinases TBK1 and IKK-É similarly activated?</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Trends Biochem Sci</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2008</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>171</sb:first-page>
                              <sb:last-page>180</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx040">Chau TL, Gioia R, Gatot JS, Patrascu F, Carpentier I, Chapelle JP, et al. Are the IKKs and IKK-related kinases TBK1 and IKK-É similarly activated? Trends Biochem Sci 2008; 33: 171â180.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0025">
                     <ce:label>5</ce:label>
                     <sb:reference id="h0025">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Wild</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Farhan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>McEwan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wagner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.V.</ce:given-name>
                                 <ce:surname>Rogov</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.R.</ce:given-name>
                                 <ce:surname>Brady</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphorylation of the autophagy receptor optineurin restricts salmonella growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>333</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>228</sb:first-page>
                              <sb:last-page>233</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx045">Wild P, Farhan H, McEwan DG, Wagner S, Rogov VV, Brady NR, et al. Phosphorylation of the autophagy receptor optineurin restricts salmonella growth. Science 2011; 333: 228â233.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0030">
                     <ce:label>6</ce:label>
                     <sb:reference id="h0030">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.A.</ce:given-name>
                                 <ce:surname>Fitzgerald</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Mcwhirter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.L.</ce:given-name>
                                 <ce:surname>Faia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.C.</ce:given-name>
                                 <ce:surname>Rowe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Latz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.T.</ce:given-name>
                                 <ce:surname>Golenbock</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>IKKÎµ and TBK1 are essential components of the IRF3 signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat Immunol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>491</sb:first-page>
                              <sb:last-page>496</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx050">Fitzgerald KA, Mcwhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, et al. IKKÎµ and TBK1 are essential components of the IRF3 signaling pathway. Nat Immunol 2003; 4: 491â496.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0035">
                     <ce:label>7</ce:label>
                     <sb:reference id="h0035">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hasan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Pharmacol Res</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>111</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>336</sb:first-page>
                              <sb:last-page>342</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx055">Hasan M, Yan N. Therapeutic potential of targeting TBK1 in autoimmune diseases and interferonopathies. Pharmacol Res 2016; 111: 336â342.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0040">
                     <ce:label>8</ce:label>
                     <sb:reference id="h0040">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Matsumoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Shimogori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Hattori</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Nukina</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TBK1 controls autophagosomal engulfment of polyubiquitinated mitochondria through p62/SQSTM1 phosphorylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Hum Mol Genet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4429</sb:first-page>
                              <sb:last-page>4442</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx060">Matsumoto G, Shimogori T, Hattori N, Nukina N. TBK1 controls autophagosomal engulfment of polyubiquitinated mitochondria through p62/SQSTM1 phosphorylation. Hum Mol Genet 2015; 24: 4429â4442.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0045">
                     <ce:label>9</ce:label>
                     <sb:reference id="h0045">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Richter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Sliter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Herhaus</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Stolz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Beli</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged mitochondria</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc Natl Acad Sci USA</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>113</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4039</sb:first-page>
                              <sb:last-page>4044</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx065">Richter B, Sliter DA, Herhaus L, Stolz A, Wang C, Beli P, et al. Phosphorylation of OPTN by TBK1 enhances its binding to Ub chains and promotes selective autophagy of damaged mitochondria. Proc Natl Acad Sci USA 2016; 113: 4039â4044.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0050">
                     <ce:label>10</ce:label>
                     <sb:reference id="h0050">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Barbie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Tamayo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.S.</ce:given-name>
                                 <ce:surname>Boehm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.E.</ce:given-name>
                                 <ce:surname>Moody</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.F.</ce:given-name>
                                 <ce:surname>Dunn</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>462</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>108</sb:first-page>
                              <sb:last-page>112</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx070">Barbie DA, Tamayo P, Boehm JS, Kim SY, Moody SE, Dunn IF, et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462: 108â112.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0055">
                     <ce:label>11</ce:label>
                     <sb:reference id="h0055">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Imamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>Jenkins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Canadas</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kitajima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Aref</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Autophagy inhibition dysregulates TBK1 signaling and promotes pancreatic inflammation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Immunol Res</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>520</sb:first-page>
                              <sb:last-page>530</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx075">Yang SH, Imamura Y, Jenkins RW, Canadas I, Kitajima S, Aref A, et al. Autophagy inhibition dysregulates TBK1 signaling and promotes pancreatic inflammation. Cancer Immunol Res 2016; 4: 520â530.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0060">
                     <ce:label>12</ce:label>
                     <sb:reference id="h0060">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Xiao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Zou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.S.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Jie</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The kinase TBK1 functions in dendritic cells to regulate T cell homeostasis, autoimmunity, and antitumor immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Exp Med</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>214</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1493</sb:first-page>
                              <sb:last-page>1507</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx080">Xiao YC, Zou Q, Xie X, Liu T, Li HS, Jie Z, et al. The kinase TBK1 functions in dendritic cells to regulate T cell homeostasis, autoimmunity, and antitumor immunity. J Exp Med 2017; 214: 1493â1507.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0065">
                     <ce:label>13</ce:label>
                     <sb:reference id="h0065">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Eguchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Nagai</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Islet inflammation in type 2 diabetes and physiology</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Clin Invest</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>127</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>14</sb:first-page>
                              <sb:last-page>23</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx085">Eguchi K, Nagai R. Islet inflammation in type 2 diabetes and physiology. J Clin Invest 2017; 127: 14â23.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0070">
                     <ce:label>14</ce:label>
                     <sb:reference id="h0070">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.F.</ce:given-name>
                                 <ce:surname>Jia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Tapadar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Weaver</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.O.</ce:given-name>
                                 <ce:surname>Raji</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Pithadia</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of TBK1/IKKÎµ promotes regeneration of pancreatic Î²-cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci Rep</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>15587</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx090">Xu J, Jia YF, Tapadar S, Weaver JD, Raji IO, Pithadia DJ, et al. Inhibition of TBK1/IKKÎµ promotes regeneration of pancreatic Î²-cells. Sci Rep 2018; 8: 15587.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0075">
                     <ce:label>15</ce:label>
                     <sb:reference id="h0075">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Larabi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Devos</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.L.</ce:given-name>
                                 <ce:surname>Ng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Nanao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Round</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Maniatis</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Crystal structure and mechanism of activation of TANK-binding kinase 1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Rep</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>734</sb:first-page>
                              <sb:last-page>746</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx095">Larabi A, Devos JM, Ng SL, Nanao MH, Round A, Maniatis T, et al. Crystal structure and mechanism of activation of TANK-binding kinase 1. Cell Rep 2013; 3: 734â746.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0080">
                     <ce:label>16</ce:label>
                     <sb:reference id="h0080">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.Q.</ce:given-name>
                                 <ce:surname>Tu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.H.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.Y.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.H.</ce:given-name>
                                 <ce:surname>Yun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.E.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Toms</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structure and ubiquitination-dependent activation of TANK-binding kinase 1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Rep</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>3</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>747</sb:first-page>
                              <sb:last-page>758</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx100">Tu DQ, Zhu ZH, Zhou AY, Yun CH, Lee KE, Toms AV, et al. Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep 2013; 3: 747â758.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0085">
                     <ce:label>17</ce:label>
                     <sb:reference id="h0085">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.L.</ce:given-name>
                                 <ce:surname>Ma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Helgason</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.T.</ce:given-name>
                                 <ce:surname>Phung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Quan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.S.</ce:given-name>
                                 <ce:surname>Iyer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.W.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular basis of TANK-binding kinase 1 activation by transautophosphorylation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc Natl Acad Sci USA</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>109</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>9378</sb:first-page>
                              <sb:last-page>9383</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx105">Ma XL, Helgason E, Phung QT, Quan CL, Iyer RS, Lee MW, et al. Molecular basis of TANK-binding kinase 1 activation by transautophosphorylation. Proc Natl Acad Sci USA 2012; 109: 9378â9383.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0090">
                     <ce:label>18</ce:label>
                     <sb:reference id="h0090">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Helgason</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.T.</ce:given-name>
                                 <ce:surname>Phung</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.C.</ce:given-name>
                                 <ce:surname>Dueber</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Recent insights into the complexity of TANK-binding kinase 1 signaling networks: the emerging role of cellular localization in the activation and substrate specificity of TBK1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Febs Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>587</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1230</sb:first-page>
                              <sb:last-page>1237</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx110">Helgason E, Phung QT, Dueber EC. Recent insights into the complexity of TANK-binding kinase 1 signaling networks: the emerging role of cellular localization in the activation and substrate specificity of TBK1. Febs Lett 2013; 587: 1230â1237.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0095">
                     <ce:label>19</ce:label>
                     <sb:reference id="h0095">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.Q.</ce:given-name>
                                 <ce:surname>Lei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Zhong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.B.</ce:given-name>
                                 <ce:surname>Shu</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Glycogen synthase kinase 3Î² regulates IRF3 transcription factor-mediated antiviral response via activation of the kinase TBK1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunity</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>878</sb:first-page>
                              <sb:last-page>889</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx115">Lei CQ, Zhong B, Zhang Y, Zhang J, Wang S, Shu HB. Glycogen synthase kinase 3Î² regulates IRF3 transcription factor-mediated antiviral response via activation of the kinase TBK1. Immunity 2010; 33: 878â889.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0100">
                     <ce:label>20</ce:label>
                     <sb:reference id="h0100">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Gu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.Y.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Lai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.L.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Ouyang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>RKIP and TBK1 form a positive feedback loop to promote type I interferon production in innate immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>EMBO J</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>35</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2553</sb:first-page>
                              <sb:last-page>2565</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx120">Gu MD, Liu ZY, Lai R, Liu S, Lin WL, Ouyang C. RKIP and TBK1 form a positive feedback loop to promote type I interferon production in innate immunity. EMBO J 2016; 35: 2553â2565.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0105">
                     <ce:label>21</ce:label>
                     <sb:reference id="h0105">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.L.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Q.</ce:given-name>
                                 <ce:surname>Tang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.T.</ce:given-name>
                                 <ce:surname>Cao</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The tyrosine kinase Src promotes phosphorylation of the kinase TBK1 to facilitate type I interferon production after viral infection</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci Signal</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>eaae0435</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx125">Li XL, Yang MJ, Yu Z, Tang SQ, Wang L, Cao XT. The tyrosine kinase Src promotes phosphorylation of the kinase TBK1 to facilitate type I interferon production after viral infection. Sci Signal 2017; 10: eaae0435.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0110">
                     <ce:label>22</ce:label>
                     <sb:reference id="h0110">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.I.</ce:given-name>
                                 <ce:surname>Wong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.L.</ce:given-name>
                                 <ce:surname>Sun</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Reilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Uhm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.J.</ce:given-name>
                                 <ce:surname>Liao</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TBK1 at the crossroads of inflammation and energy homeostasis in adipose tissue</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>172</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>731</sb:first-page>
                              <sb:last-page>743</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx130">Zhao P, Wong KI, Sun XL, Reilly SM, Uhm M, Liao ZJ, et al. TBK1 at the crossroads of inflammation and energy homeostasis in adipose tissue. Cell 2018; 172: 731â743.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0115">
                     <ce:label>23</ce:label>
                     <sb:reference id="h0115">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.A.</ce:given-name>
                                 <ce:surname>Janeway</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Approaching the asymptote? Evolution and revolution in immunology</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cold Spring Harb Symp Quant Biol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>1989</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>13</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx135">Janeway CA. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol 1989; 54: 1â13.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0120">
                     <ce:label>24</ce:label>
                     <sb:reference id="h0120">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Brubaker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Bonham</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>I.</ce:given-name>
                                 <ce:surname>Zanoni</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.C.</ce:given-name>
                                 <ce:surname>Kagan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Innate immune pattern recognition: a cell biological perspective</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Annu Rev Immunol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>33</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>257</sb:first-page>
                              <sb:last-page>290</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx140">Brubaker SW, Bonham KS, Zanoni I, Kagan JC. Innate immune pattern recognition: a cell biological perspective. Annu Rev Immunol 2015; 33: 257â290.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0125">
                     <ce:label>25</ce:label>
                     <sb:reference id="h0125">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sharma</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.R.</ce:given-name>
                                 <ce:surname>Tenoever</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Grandvaux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.P.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.T.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Hiscott</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Triggering the interferon antiviral response through an IKK-related pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>300</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1148</sb:first-page>
                              <sb:last-page>1151</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx145">Sharma S, Tenoever BR, Grandvaux N, Zhou GP, Lin RT, Hiscott J. Triggering the interferon antiviral response through an IKK-related pathway. Science 2003; 300: 1148â1151.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0130">
                     <ce:label>26</ce:label>
                     <sb:reference id="h0130">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yamamoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hemmi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Hoshino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kaisho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sanjo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Science</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>301</sb:volume-nr>
                              </sb:series>
                              <sb:date>2003</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>640</sb:first-page>
                              <sb:last-page>643</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx150">Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301: 640â643.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0135">
                     <ce:label>27</ce:label>
                     <sb:reference id="h0135">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Dempsey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.G.</ce:given-name>
                                 <ce:surname>Bowie</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Innate immune recognition of DNA: A recent history</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Virology</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>479</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>146</sb:first-page>
                              <sb:last-page>152</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx155">Dempsey A, Bowie AG. Innate immune recognition of DNA: A recent history. Virology 2015; 479: 146â152.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0140">
                     <ce:label>28</ce:label>
                     <sb:reference id="h0140">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.G.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.J.</ce:given-name>
                                 <ce:surname>Shang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Gui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.W.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.C.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural basis of STING binding with and phosphorylation by TBK1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nature</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>567</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>394</sb:first-page>
                              <sb:last-page>398</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx160">Zhang CG, Shang GJ, Gui X, Zhang XW, Bai XC, Chen ZJ. Structural basis of STING binding with and phosphorylation by TBK1. Nature 2019; 567: 394â398.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0145">
                     <ce:label>29</ce:label>
                     <sb:reference id="h0145">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Cai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.H.</ce:given-name>
                                 <ce:surname>Chiu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.J.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>54</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>289</sb:first-page>
                              <sb:last-page>296</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx165">Cai X, Chiu YH, Chen ZJ. The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling. Mol Cell 2014; 54: 289â296.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0150">
                     <ce:label>30</ce:label>
                     <sb:reference id="h0150">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Hemmi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>O.</ce:given-name>
                                 <ce:surname>Takeuchi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Sato</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Yamamoto</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Kaisho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Sanjo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The roles of two IÎºB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Exp Med</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>199</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1641</sb:first-page>
                              <sb:last-page>1650</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx170">Hemmi H, Takeuchi O, Sato S, Yamamoto M, Kaisho T, Sanjo H, et al. The roles of two IÎºB kinase-related kinases in lipopolysaccharide and double stranded RNA signaling and viral infection. J Exp Med 2004; 199: 1641â1650.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0155">
                     <ce:label>31</ce:label>
                     <sb:reference id="h0155">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Chien</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bumeister</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.M.</ce:given-name>
                                 <ce:surname>Loo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.W.</ce:given-name>
                                 <ce:surname>Kwon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.L.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>RalB GTPase-mediated activation of the IÎºB family kinase TBK1 couples innate immune signaling to tumor cell survival</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>127</sb:volume-nr>
                              </sb:series>
                              <sb:date>2006</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>157</sb:first-page>
                              <sb:last-page>170</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx175">Chien YC, Kim S, Bumeister R, Loo YM, Kwon SW, Johnson CL, et al. RalB GTPase-mediated activation of the IÎºB family kinase TBK1 couples innate immune signaling to tumor cell survival. Cell 2006; 127: 157â170.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0160">
                     <ce:label>32</ce:label>
                     <sb:reference id="h0160">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Welsh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>U.</ce:given-name>
                                 <ce:surname>Oguz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Fang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Kinose</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Proc Natl Acad Sci USA</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>110</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>12414</sb:first-page>
                              <sb:last-page>12419</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx180">Kim JY, Welsh EA, Oguz U, Fang B, Bai Y, Kinose F, et al. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci USA 2013; 110: 12414â12419.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0165">
                     <ce:label>33</ce:label>
                     <sb:reference id="h0165">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Pillai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Nguyen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Johnson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Haura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Coppola</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chellappan</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TANK binding kinase 1 is a centrosome-associated kinase necessary for microtubule dynamics and mitosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat Commun</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>10072</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx185">Pillai S, Nguyen J, Johnson J, Haura E, Coppola D, Chellappan S. TANK binding kinase 1 is a centrosome-associated kinase necessary for microtubule dynamics and mitosis. Nat Commun 2015; 6: 10072.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0170">
                     <ce:label>34</ce:label>
                     <sb:reference id="h0170">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.H.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Aref</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.J.</ce:given-name>
                                 <ce:surname>Cohoon</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.U.</ce:given-name>
                                 <ce:surname>Barbie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Imamura</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Discov</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>452</sb:first-page>
                              <sb:last-page>465</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx190">Zhu ZH, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang SH, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov 2014; 4: 452â465.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0175">
                     <ce:label>35</ce:label>
                     <sb:reference id="h0175">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Kitajima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Asahina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.G.</ce:given-name>
                                 <ce:surname>Quiceno</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.D.</ce:given-name>
                                 <ce:surname>Cavanaugh</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Overcoming resistance to dual innate immune and mEK inhibition downstream of KRAS</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>34</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>439</sb:first-page>
                              <sb:last-page>452</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx195">Kitajima S, Asahina H, Chen T, Guo SJ, Quiceno LG, Cavanaugh JD, et al. Overcoming resistance to dual innate immune and mEK inhibition downstream of KRAS. Cancer Cell 2018; 34: 439â452.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0180">
                     <ce:label>36</ce:label>
                     <sb:reference id="h0180">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.Q.</ce:given-name>
                                 <ce:surname>Ying</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Dey</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.T.</ce:given-name>
                                 <ce:surname>Yao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.C.</ce:given-name>
                                 <ce:surname>Kimmelman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.F.</ce:given-name>
                                 <ce:surname>Draetta</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Maitra</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Genetics and biology of pancreatic ductal adenocarcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Genes Dev</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>30</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>355</sb:first-page>
                              <sb:last-page>385</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx200">Ying HQ, Dey P, Yao WT, Kimmelman AC, Draetta GF, Maitra A, et al. Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev 2016; 30: 355â385.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0185">
                     <ce:label>37</ce:label>
                     <sb:reference id="h0185">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.H.</ce:given-name>
                                 <ce:surname>Cruz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.N.</ce:given-name>
                                 <ce:surname>Arner</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.T.</ce:given-name>
                                 <ce:surname>Du</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.E.</ce:given-name>
                                 <ce:surname>Bremauntz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Brekken</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>JCI insight</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>4</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>e126117</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx205">Cruz VH, Arner EN, Du WT, Bremauntz AE, Brekken RA. Axl-mediated activation of TBK1 drives epithelial plasticity in pancreatic cancer. JCI insight 2019; 4: e126117.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0190">
                     <ce:label>38</ce:label>
                     <sb:reference id="h0190">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Y.H.</ce:given-name>
                                 <ce:surname>Ou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Torres</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Ram</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Formstecher</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Roland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>41</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>458</sb:first-page>
                              <sb:last-page>470</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx210">Ou YH, Torres M, Ram R, Formstecher E, Roland C, Cheng T, et al. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell 2011; 41: 458â470.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0195">
                     <ce:label>39</ce:label>
                     <sb:reference id="h0195">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Muvaffak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Pan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.Y.</ce:given-name>
                                 <ce:surname>Yan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Fernandez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Dolinski</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Evaluating TBK1 as a therapeutic target in cancers with activated IRF3</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol Cancer Res</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1055</sb:first-page>
                              <sb:last-page>1066</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx215">Muvaffak A, Pan Q, Yan HY, Fernandez R, Lim J, Dolinski B, et al. Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. Mol Cancer Res 2014; 12: 1055â1066.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0200">
                     <ce:label>40</ce:label>
                     <sb:reference id="h0200">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.X.</ce:given-name>
                                 <ce:surname>Hu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.B.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.J.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Potjewyd</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.I.</ce:given-name>
                                 <ce:surname>James</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.M.</ce:given-name>
                                 <ce:surname>Wilkerson</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TBK1 is a synthetic lethal target in cancer with VHL loss</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Discov</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>460</sb:first-page>
                              <sb:last-page>475</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx220">Hu LX, Xie HB, Liu XJ, Potjewyd F, James LI, Wilkerson EM, et al. TBK1 is a synthetic lethal target in cancer with VHL loss. Cancer Discov 2020; 10: 460â475.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0205">
                     <ce:label>41</ce:label>
                     <sb:reference id="h0205">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.R.</ce:given-name>
                                 <ce:surname>Gnarra</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Tory</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.</ce:given-name>
                                 <ce:surname>Weng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Schmidt</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.H.</ce:given-name>
                                 <ce:surname>Wei</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Mutations of the VHL tumour suppressor gene in renal carcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat Genet</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>1994</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>85</sb:first-page>
                              <sb:last-page>90</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx225">Gnarra JR, Tory K, Weng Y, Schmidt L, Wei MH, Li H, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994; 7: 85â90.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0210">
                     <ce:label>42</ce:label>
                     <sb:reference id="h0210">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Levine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.J.</ce:given-name>
                                 <ce:surname>Klionsky</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Development by self-digestion: molecular mechanisms and biological functions of autophagy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Dev Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2004</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>463</sb:first-page>
                              <sb:last-page>477</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx230">Levine B, Klionsky DJ. Development by self-digestion: molecular mechanisms and biological functions of autophagy. Dev Cell 2004; 6: 463â477.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0215">
                     <ce:label>43</ce:label>
                     <sb:reference id="h0215">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Rybstein</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.B.</ce:given-name>
                                 <ce:surname>Pedro</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Kroemer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Galluzzi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The autophagic network and cancer</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat Cell Biol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>243</sb:first-page>
                              <sb:last-page>251</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx235">Rybstein MD, Pedro JMB, Kroemer G, Galluzzi L. The autophagic network and cancer. Nat Cell Biol 2018; 20: 243â251.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0220">
                     <ce:label>44</ce:label>
                     <ce:other-ref id="h0220">
                        <ce:textref>Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med 2013;19:983â97.</ce:textref>
                     </ce:other-ref>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0225">
                     <ce:label>45</ce:label>
                     <sb:reference id="h0225">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>G.M.</ce:given-name>
                                 <ce:surname>Fimia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Kroemer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Piacentini</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Molecular mechanisms of selective autophagy</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Death Differ</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>20</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1</sb:first-page>
                              <sb:last-page>2</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx240">Fimia GM, Kroemer G, Piacentini M. Molecular mechanisms of selective autophagy. Cell Death Differ 2013; 20: 1â2.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0230">
                     <ce:label>46</ce:label>
                     <sb:reference id="h0230">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Pilli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Arkomensah</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Ponpuak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Roberts</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Master</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Mandell</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Immunity</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>223</sb:first-page>
                              <sb:last-page>234</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx245">Pilli M, Arkomensah J, Ponpuak M, Roberts E, Master S, Mandell MA, et al. TBK-1 promotes autophagy-mediated antimicrobial defense by controlling autophagosome maturation. Immunity 2012; 37: 223â234.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0235">
                     <ce:label>47</ce:label>
                     <sb:reference id="h0235">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>F.X.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.Q.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.L.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.P.</ce:given-name>
                                 <ce:surname>Liu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.F.</ce:given-name>
                                 <ce:surname>Cheng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.J.</ce:given-name>
                                 <ce:surname>Guo</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Structural insights into the interaction and disease mechanism of neurodegenerative diseaseâassociated optineurin and TBK1 proteins</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat Commun</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>7</sb:volume-nr>
                              </sb:series>
                              <sb:date>2016</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>12708</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx250">Li FX, Xie XQ, Wang YL, Liu JP, Cheng XF, Guo YJ, et al. Structural insights into the interaction and disease mechanism of neurodegenerative diseaseâassociated optineurin and TBK1 proteins. Nat Commun 2016; 7: 12708.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0240">
                     <ce:label>48</ce:label>
                     <sb:reference id="h0240">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>V.</ce:given-name>
                                 <ce:surname>Gerbino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Esther</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Q.</ce:given-name>
                                 <ce:surname>Ye</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Canzio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>OâKeeffe</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.D.</ce:given-name>
                                 <ce:surname>Rudnick</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The loss of TBK1 kinase activity in motor neurons or in all cell types differentially impacts ALS disease progression in SOD1 mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Neuron</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>106</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>789</sb:first-page>
                              <sb:last-page>805</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx255">Gerbino V, Esther K, Ye JQ, Canzio D, OâKeeffe S, Rudnick ND, et al. The loss of TBK1 kinase activity in motor neurons or in all cell types differentially impacts ALS disease progression in SOD1 mice. Neuron 2020; 106: 789â805.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0245">
                     <ce:label>49</ce:label>
                     <sb:reference id="h0245">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Blokhuis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.J.N.</ce:given-name>
                                 <ce:surname>Groen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Koppers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.H.</ce:given-name>
                                 <ce:surname>Berg</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Pasterkamp</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Protein aggregation in amyotrophic lateral sclerosis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Acta Neuropathol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>125</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>777</sb:first-page>
                              <sb:last-page>794</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx260">Blokhuis AM, Groen EJN, Koppers M, Berg LH, Pasterkamp RJ. Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol 2013; 125: 777â794.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0250">
                     <ce:label>50</ce:label>
                     <sb:reference id="h0250">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.N.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.S.</ce:given-name>
                                 <ce:surname>Hertersprie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.K.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.Y.</ce:given-name>
                                 <ce:surname>Lin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Biancur</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Autophagy sustains pancreatic cancer growth through both cell-autonomous and nonautonomous mechanisms</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Discov</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>276</sb:first-page>
                              <sb:last-page>287</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx265">Yang AN, Hertersprie GS, Zhang HK, Lin EY, Biancur D, Wang XX, et al. Autophagy sustains pancreatic cancer growth through both cell-autonomous and nonautonomous mechanisms. Cancer Discov 2018; 8: 276â287.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0255">
                     <ce:label>51</ce:label>
                     <sb:reference id="h0255">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.X.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Contino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Liesa</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Sahin</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.Q.</ce:given-name>
                                 <ce:surname>Ying</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Pancreatic cancers require autophagy for tumor growth</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Genes Dev</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>25</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>717</sb:first-page>
                              <sb:last-page>729</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx270">Yang SH, Wang XX, Contino G, Liesa M, Sahin E, Ying HQ, et al. Pancreatic cancers require autophagy for tumor growth. Genes Dev 2011; 25: 717â729.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0260">
                     <ce:label>52</ce:label>
                     <sb:reference id="h0260">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Maueroder</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.E.</ce:given-name>
                                 <ce:surname>Munoz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.A.</ce:given-name>
                                 <ce:surname>Chaurio</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Herrmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Schett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Berens</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Tumor immunotherapy: lessons from autoimmunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Front Immunol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>5</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>212</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx275">Maueroder C, Munoz LE, Chaurio RA, Herrmann M, Schett G, Berens C. Tumor immunotherapy: lessons from autoimmunity. Front Immunol 2014; 5: 212.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0265">
                     <ce:label>53</ce:label>
                     <sb:reference id="h0265">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.W.</ce:given-name>
                                 <ce:surname>Jenkins</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Aref</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.H.</ce:given-name>
                                 <ce:surname>Lizotte</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Ivanova</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Stinson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Discov</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>196</sb:first-page>
                              <sb:last-page>215</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx280">Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, Zhou CW, et al. Ex vivo profiling of PD-1 blockade using organotypic tumor spheroids. Cancer Discov 2017; 8: 196â215.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0270">
                     <ce:label>54</ce:label>
                     <sb:reference id="h0270">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.L.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.P.</ce:given-name>
                                 <ce:surname>Xie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.F.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.D.</ce:given-name>
                                 <ce:surname>Gu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.L.</ce:given-name>
                                 <ce:surname>Jie</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat Cell Biol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>21</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1604</sb:first-page>
                              <sb:last-page>1614</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx285">Zhu LL, Li YC, Xie XP, Zhou XF, Gu MD, Jie ZL, et al. TBKBP1 and TBK1 form a growth factor signalling axis mediating immunosuppression and tumourigenesis. Nat Cell Biol 2019; 21: 1604â1614.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0275">
                     <ce:label>55</ce:label>
                     <sb:reference id="h0275">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Chiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Bazuine</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.N.</ce:given-name>
                                 <ce:surname>Lumeng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.M.</ce:given-name>
                                 <ce:surname>Geletka</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Mowers</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.M.</ce:given-name>
                                 <ce:surname>White</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The protein kinase IKK epsilon regulates energy balance in obese mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>138</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>961</sb:first-page>
                              <sb:last-page>975</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx290">Chiang SH, Bazuine M, Lumeng CN, Geletka LM, Mowers J, White NM, et al. The protein kinase IKK epsilon regulates energy balance in obese mice. Cell 2009; 138: 961â975.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0280">
                     <ce:label>56</ce:label>
                     <ce:other-ref id="h0280">
                        <ce:textref>Mowers J, Uhm M, Reilly SM, Simon J, Leto D, Chiang SH, et al. Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKÎµ and TBK1. eLife 2013;2: e01119.</ce:textref>
                     </ce:other-ref>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0285">
                     <ce:label>57</ce:label>
                     <sb:reference id="h0285">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Yehuda-Shnaidman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Buehrer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Pi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Kumar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Collins</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Acute stimulation of white adipocyte respiration by PKA-induced lipolysis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Diabetes</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>59</sb:volume-nr>
                              </sb:series>
                              <sb:date>2010</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2474</sb:first-page>
                              <sb:last-page>2483</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx295">Yehuda-Shnaidman E, Buehrer B, Pi JB, Kumar N, Collins S. Acute stimulation of white adipocyte respiration by PKA-induced lipolysis. Diabetes 2010; 59: 2474â2483.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0290">
                     <ce:label>58</ce:label>
                     <sb:reference id="h0290">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Reilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.H.</ce:given-name>
                                 <ce:surname>Chiang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.J.</ce:given-name>
                                 <ce:surname>Decker</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Uhm</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Larsen</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An inhibitor of the protein kinases TBK1 and IKK-É improves obesity-related metabolic dysfunctions in mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Nat Med</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2013</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>313</sb:first-page>
                              <sb:last-page>321</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx300">Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, Larsen MJ, et al. An inhibitor of the protein kinases TBK1 and IKK-É improves obesity-related metabolic dysfunctions in mice. Nat Med 2013; 19: 313â321.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0295">
                     <ce:label>59</ce:label>
                     <sb:reference id="h0295">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>C.G.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.M.</ce:given-name>
                                 <ce:surname>Cohrs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Stertmann</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Bozsak</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Speier</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Human beta cell mass and function in diabetes: recent advances in knowledge and technologies to understand disease pathogenesis</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol Metab</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>6</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>943</sb:first-page>
                              <sb:last-page>957</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx305">Chen CG, Cohrs CM, Stertmann J, Bozsak R, Speier S. Human beta cell mass and function in diabetes: recent advances in knowledge and technologies to understand disease pathogenesis. Mol Metab 2017; 6: 943â957.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0300">
                     <ce:label>60</ce:label>
                     <sb:reference id="h0300">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.C.</ce:given-name>
                                 <ce:surname>Munoz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.F.</ce:given-name>
                                 <ce:surname>Giani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Mayer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.E.</ce:given-name>
                                 <ce:surname>Toblli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Turyn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.P.</ce:given-name>
                                 <ce:surname>Dominici</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TANK-binding kinase 1 mediates phosphorylation of insulin receptor at serine residue 994: a potential link between inflammation and insulin resistance</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Endocrinol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>201</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>185</sb:first-page>
                              <sb:last-page>197</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx310">Munoz MC, Giani JF, Mayer MA, Toblli JE, Turyn D, Dominici FP. TANK-binding kinase 1 mediates phosphorylation of insulin receptor at serine residue 994: a potential link between inflammation and insulin resistance. J Endocrinol 2009; 201: 185â197.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0305">
                     <ce:label>61</ce:label>
                     <sb:reference id="h0305">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Huh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Reilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Abu-Odeh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.N.</ce:given-name>
                                 <ce:surname>Murphy</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.K.</ce:given-name>
                                 <ce:surname>Mahata</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.Y.</ce:given-name>
                                 <ce:surname>Zhang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TANK-binding kinase 1 regulates the localization of Acyl-CoA synthetase ACSL1 to control hepatic fatty acid oxidation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Metab</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>32</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1012</sb:first-page>
                              <sb:last-page>1027</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx315">Huh JY, Reilly SM, Abu-Odeh M, Murphy AN, Mahata SK, Zhang JY, et al. TANK-binding kinase 1 regulates the localization of Acyl-CoA synthetase ACSL1 to control hepatic fatty acid oxidation. Cell Metab 2020; 32: 1012â1027.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0310">
                     <ce:label>62</ce:label>
                     <sb:reference id="h0310">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.</ce:given-name>
                                 <ce:surname>Xia</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.C.</ce:given-name>
                                 <ce:surname>Yao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zeng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Amlexanox reversed non-alcoholic fatty liver disease through IKKÎµ inhibition of hepatic stellate cell</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Life Sci</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>239</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>117010</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx320">He Q, Xia X, Yao KC, Zeng J, Wang W, Wu Q, et al. Amlexanox reversed non-alcoholic fatty liver disease through IKKÎµ inhibition of hepatic stellate cell. Life Sci 2019; 239: 117010.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0315">
                     <ce:label>63</ce:label>
                     <sb:reference id="h0315">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Beyett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.M.</ce:given-name>
                                 <ce:surname>Gan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Reilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Gomez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.R.</ce:given-name>
                                 <ce:surname>Saltiel</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Carboxylic acid derivatives of amlexanox display enhanced potency toward TBK1 and IKKÎµ and reveal mechanisms for selective inhibition</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol Pharmacol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>94</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1210</sb:first-page>
                              <sb:last-page>1219</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx325">Beyett TS, Gan XM, Reilly SM, Chang L, Gomez AV, Saltiel AR, et al. Carboxylic acid derivatives of amlexanox display enhanced potency toward TBK1 and IKKÎµ and reveal mechanisms for selective inhibition. Mol Pharmacol 2018; 94: 1210â1219.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0320">
                     <ce:label>64</ce:label>
                     <sb:reference id="h0320">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Oral</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Reilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Gomez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Meral</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Butz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Ajluni</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Inhibition of IKKÉ and TBK1 improves glucose control in a subset of patients with type 2 diabetes</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cell Metab</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>157</sb:first-page>
                              <sb:last-page>170</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx330">Oral EA, Reilly SM, Gomez AV, Meral R, Butz L, Ajluni N, et al. Inhibition of IKKÉ and TBK1 improves glucose control in a subset of patients with type 2 diabetes. Cell Metab 2017; 26: 157â170.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0325">
                     <ce:label>65</ce:label>
                     <sb:reference id="h0325">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.X.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Amlexanox ameliorates acetaminophenâinduced acute liver injury by reducing oxidative stress in mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Toxicol Appl Pharmacol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>385</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:article-number>114767</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx335">Qi J, Zhou ZX, Lim CW, Kim JW, Kim B. Amlexanox ameliorates acetaminophenâinduced acute liver injury by reducing oxidative stress in mice. Toxicol Appl Pharmacol 2019; 385: 114767.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0330">
                     <ce:label>66</ce:label>
                     <sb:reference id="h0330">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>Z.X.</ce:given-name>
                                 <ce:surname>Zhou</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Qi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Zhao</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.W.</ce:given-name>
                                 <ce:surname>Lim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Dual TBK1/IKKÉ inhibitor amlexanox attenuates the severity of hepatotoxin-induced liver fibrosis and biliary fibrosis in mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Cell Mol Med</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1383</sb:first-page>
                              <sb:last-page>1398</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx340">Zhou ZX, Qi J, Zhao J, Lim CW, Kim JW, Kim B. Dual TBK1/IKKÉ inhibitor amlexanox attenuates the severity of hepatotoxinâinduced liver fibrosis and biliary fibrosis in mice. J Cell Mol Med 2020; 24: 1383â1398.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0335">
                     <ce:label>67</ce:label>
                     <sb:reference id="h0335">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.S.</ce:given-name>
                                 <ce:surname>Beyett</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.M.</ce:given-name>
                                 <ce:surname>Gan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.M.</ce:given-name>
                                 <ce:surname>Reilly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.V.</ce:given-name>
                                 <ce:surname>Gomez</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.J.</ce:given-name>
                                 <ce:surname>Tesmer</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Design, synthesis, and biological activity of substituted 2-amino-5-oxo-5H-chromeno [2, 3-b] pyridine-3-carboxylic acid derivatives as inhibitors of the inflammatory kinases TBK1 and IKKÎµ for the treatment of obesity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg Med Chem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>26</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>5443</sb:first-page>
                              <sb:last-page>5461</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx345">Beyett TS, Gan XM, Reilly SM, Gomez AV, Chang L, Tesmer JJ, et al. Design, synthesis, and biological activity of substituted 2-amino-5-oxo-5H-chromeno [2, 3-b] pyridine-3-carboxylic acid derivatives as inhibitors of the inflammatory kinases TBK1 and IKKÎµ for the treatment of obesity. Bioorg Med Chem 2018; 26: 5443â5461.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0340">
                     <ce:label>68</ce:label>
                     <sb:reference id="h0340">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>R.I.</ce:given-name>
                                 <ce:surname>Feldman</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.M.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Polokoff</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.J.</ce:given-name>
                                 <ce:surname>Kochanny</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Dinter</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.G.</ce:given-name>
                                 <ce:surname>Zhu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Biol Chem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>280</sb:volume-nr>
                              </sb:series>
                              <sb:date>2005</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>19867</sb:first-page>
                              <sb:last-page>19874</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx350">Feldman RI, Wu JM, Polokoff MA, Kochanny MJ, Dinter H, Zhu DG, et al. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1. J Biol Chem 2005; 280: 19867â19874.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0345">
                     <ce:label>69</ce:label>
                     <sb:reference id="h0345">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Clark</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Plater</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Peggie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>P.</ce:given-name>
                                 <ce:surname>Cohen</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IÎºB Kinase âa distinct upstream kinase mediates SER-172 phosphorylation and activation</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Biol Chem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>284</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>14136</sb:first-page>
                              <sb:last-page>14146</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx355">Clark K, Plater L, Peggie M, Cohen P. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IÎºB Kinase â a distinct upstream kinase mediates SER-172 phosphorylation and activation. J Biol Chem 2009; 284: 14136â14146.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0350">
                     <ce:label>70</ce:label>
                     <sb:reference id="h0350">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.B.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Jie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>X.X.</ce:given-name>
                                 <ce:surname>Fu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Xu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>The kinase inhibitor BX795 suppresses the inflammatory response via multiple kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem Pharmacol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>174</sb:volume-nr>
                              </sb:series>
                              <sb:date>2020</sb:date>
                           </sb:issue>
                           <sb:article-number>113797</sb:article-number>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx360">Yu T, Wang ZB, Jie W, Fu XX, Li B, Xu H, et al. The kinase inhibitor BX795 suppresses the inflammatory response via multiple kinases. Biochem Pharmacol 2020; 174: 113797.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0355">
                     <ce:label>71</ce:label>
                     <sb:reference id="h0355">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Jaishankar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Yakoub</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Yadavalli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Agelidis</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Thakkar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Hadigal</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>An off-target effect of BX795 blocks herpes simplex virus type 1 infection of the eye</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Sci Transl Med</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>eaan5861</sb:first-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx365">Jaishankar D, Yakoub AM, Yadavalli T, Agelidis A, Thakkar N, Hadigal S, et al. An off-target effect of BX795 blocks herpes simplex virus type 1 infection of the eye. Sci Transl Med 2018; 10: eaan5861.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0360">
                     <ce:label>72</ce:label>
                     <sb:reference id="h0360">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>L.Y.</ce:given-name>
                                 <ce:surname>Bai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.F.</ce:given-name>
                                 <ce:surname>Chiu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.P.</ce:given-name>
                                 <ce:surname>Kapuriya</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.M.</ce:given-name>
                                 <ce:surname>Shieh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.C.</ce:given-name>
                                 <ce:surname>Tsai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.Y.</ce:given-name>
                                 <ce:surname>Wu</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>BX795, a TBK1 inhibitor, exhibits antitumor activity in human oral squamous cell carcinoma through apoptosis induction and mitotic phase arrest</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Eur J Pharmacol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>769</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>287</sb:first-page>
                              <sb:last-page>296</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx370">Bai LY, Chiu CF, Kapuriya NP, Shieh TM, Tsai YC, Wu CY, et al. BX795, a TBK1 inhibitor, exhibits antitumor activity in human oral squamous cell carcinoma through apoptosis induction and mitotic phase arrest. Eur J Pharmacol 2015; 769: 287â296.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0365">
                     <ce:label>73</ce:label>
                     <sb:reference id="h0365">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Chen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.W.</ce:given-name>
                                 <ce:surname>Luo</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Z.Y.</ce:given-name>
                                 <ce:surname>Ke</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Kuai</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.Y.</ce:given-name>
                                 <ce:surname>He</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>W.</ce:given-name>
                                 <ce:surname>Jiang</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>TBK1 promote bladder cancer cell proliferation and migration via Akt signaling</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>8</sb:volume-nr>
                              </sb:series>
                              <sb:date>2017</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1892</sb:first-page>
                              <sb:last-page>1899</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx375">Chen W, Luo KW, Ke ZY, Kuai B, He SY, Jiang W, et al. TBK1 promote bladder cancer cell proliferation and migration via Akt signaling. J Cancer 2017; 8: 1892â1899.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0370">
                     <ce:label>74</ce:label>
                     <sb:reference id="h0370">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>E.A.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.S.</ce:given-name>
                                 <ce:surname>Choi</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.J.</ce:given-name>
                                 <ce:surname>Lee</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.R.</ce:given-name>
                                 <ce:surname>Singh</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.C.</ce:given-name>
                                 <ce:surname>Kim</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Chang</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>A pharmacogenomic analysis using L1000CDS2 identifies BX-795 as a potential anticancer drug for primary pancreatic ductal adenocarcinoma cells</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Cancer Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>465</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>82</sb:first-page>
                              <sb:last-page>93</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx380">Choi EA, Choi YS, Lee EJ, Singh SR, Kim SC, Chang S. A pharmacogenomic analysis using L1000CDS2 identifies BX-795 as a potential anticancer drug for primary pancreatic ductal adenocarcinoma cells. Cancer Lett 2019; 465: 82â93.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0375">
                     <ce:label>75</ce:label>
                     <sb:reference id="h0375">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Clark</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Peggie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Plater</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.J.</ce:given-name>
                                 <ce:surname>Sorcek</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.R.</ce:given-name>
                                 <ce:surname>Young</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.B.</ce:given-name>
                                 <ce:surname>Madwed</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Novel cross-talk within the IKK family controls innate immunity</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Biochem J</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>434</sb:volume-nr>
                              </sb:series>
                              <sb:date>2011</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>93</sb:first-page>
                              <sb:last-page>104</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx385">Clark K, Peggie M, Plater L, Sorcek RJ, Young ER, Madwed JB, et al. Novel cross-talk within the IKK family controls innate immunity. Biochem J 2011; 434: 93â104.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0380">
                     <ce:label>76</ce:label>
                     <sb:reference id="h0380">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Pardanani</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>T.L.</ce:given-name>
                                 <ce:surname>Lasho</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>G.</ce:given-name>
                                 <ce:surname>Smith</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.J.</ce:given-name>
                                 <ce:surname>Burns</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Fantino</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Tefferi</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>CYT387, a selective JAK1/JAK2 inhibitor: <ce:italic>in vitro</ce:italic> assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Leukemia</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>23</sb:volume-nr>
                              </sb:series>
                              <sb:date>2009</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1441</sb:first-page>
                              <sb:last-page>1445</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx390">Pardanani A, Lasho TL, Smith G, Burns CJ, Fantino E, Tefferi A. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients. Leukemia 2009; 23: 1441â1445.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0385">
                     <ce:label>77</ce:label>
                     <sb:reference id="h0385">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.A.</ce:given-name>
                                 <ce:surname>Barbie</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Alexander</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Kelly</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.</ce:given-name>
                                 <ce:surname>Humeniuk</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Kawashima</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.S.</ce:given-name>
                                 <ce:surname>Chun</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase 1B study of momelotinib combined with trametinib in metastatic, kirsten rat sarcoma viral oncogene homolog - mutated nonâsmall-cell lung cancer after platinum-based chemotherapy treatment failure</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Clin Lung Cancer</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>19</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>853</sb:first-page>
                              <sb:last-page>859</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx395">Barbie DA, Alexander S, Kelly K, Humeniuk R, Kawashima J, Chun KS, et al. Phase 1B study of momelotinib combined with trametinib in metastatic, kirsten rat sarcoma viral oncogene homolog - mutated nonâsmall-cell lung cancer after platinum-based chemotherapy treatment failure. Clin Lung Cancer 2018; 19: 853â859.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0390">
                     <ce:label>78</ce:label>
                     <sb:reference id="h0390">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Ng</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Hendifar</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Starodub</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Chaves</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.S.</ce:given-name>
                                 <ce:surname>Yang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>B.</ce:given-name>
                                 <ce:surname>Koh</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Invest New Drugs</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>37</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>159</sb:first-page>
                              <sb:last-page>165</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx400">Ng K, Hendifar A, Starodub A, Chaves J, Yang YS, Koh B, et al. Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma. Invest New Drugs 2018; 37: 159â165.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0395">
                     <ce:label>79</ce:label>
                     <sb:reference id="h0395">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>D.W.</ce:given-name>
                                 <ce:surname>Thomson</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Poeckel</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Zinn</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Rau</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Strohmer</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.J.</ce:given-name>
                                 <ce:surname>Wagner</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of GSK8612, a highly selective and potent TBK1 inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>ACS Medicinal Chem Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>10</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>780</sb:first-page>
                              <sb:last-page>785</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx405">Thomson DW, Poeckel D, Zinn N, Rau C, Strohmer K, Wagner AJ, et al. Discovery of GSK8612, a highly selective and potent TBK1 inhibitor. ACS Medicinal Chem Lett 2019; 10: 780â785.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0400">
                     <ce:label>80</ce:label>
                     <sb:reference id="h0400">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>T.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>Block</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Cowen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.M.</ce:given-name>
                                 <ce:surname>Davies</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Devereaux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Gingipalli</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKepsilon kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorganic Med Chem Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>22</sb:volume-nr>
                              </sb:series>
                              <sb:date>2012</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>2063</sb:first-page>
                              <sb:last-page>2069</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx410">Wang T, Block MA, Cowen S, Davies AM, Devereaux E, Gingipalli L, et al. Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKepsilon kinases. Bioorganic Med Chem Lett 2012; 22: 2063â2069.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0405">
                     <ce:label>81</ce:label>
                     <sb:reference id="h0405">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.W.</ce:given-name>
                                 <ce:surname>Johannes</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>C.</ce:given-name>
                                 <ce:surname>Chuaqui</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Cowen</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.</ce:given-name>
                                 <ce:surname>Devereaux</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>L.</ce:given-name>
                                 <ce:surname>Gingipalli</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Molina</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of 6-aryl-azabenzimidazoles that inhibit the TBK1/IKK-epsilon kinases</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Bioorg Med Chem Lett</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>24</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1138</sb:first-page>
                              <sb:last-page>1143</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx415">Johannes JW, Chuaqui C, Cowen S, Devereaux E, Gingipalli L, Molina A, et al. Discovery of 6-aryl-azabenzimidazoles that inhibit the TBK1/IKK-epsilon kinases. Bioorg Med Chem Lett 2014; 24: 1138â1143.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0410">
                     <ce:label>82</ce:label>
                     <sb:reference id="h0410">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>H.L.</ce:given-name>
                                 <ce:surname>Vu</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.E.</ce:given-name>
                                 <ce:surname>Aplin</ce:surname>
                              </sb:author>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>Mol Cancer Res</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>12</sb:volume-nr>
                              </sb:series>
                              <sb:date>2014</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>1509</sb:first-page>
                              <sb:last-page>1519</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx420">Vu HL, Aplin AE. Targeting TBK1 inhibits migration and resistance to MEK inhibitors in mutant NRAS melanoma. Mol Cancer Res 2014; 12: 1509â1519.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0415">
                     <ce:label>83</ce:label>
                     <sb:reference id="h0415">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>M.</ce:given-name>
                                 <ce:surname>Hasan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>N.</ce:given-name>
                                 <ce:surname>Dobbs</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>S.</ce:given-name>
                                 <ce:surname>Khan</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>M.A.</ce:given-name>
                                 <ce:surname>White</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>E.K.</ce:given-name>
                                 <ce:surname>Wakeland</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Q.Z.</ce:given-name>
                                 <ce:surname>Li</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Cutting edge: inhibiting TBK1 by compound II ameliorates autoimmune disease in mice</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Immunol</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>195</sb:volume-nr>
                              </sb:series>
                              <sb:date>2015</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>4573</sb:first-page>
                              <sb:last-page>4577</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx425">Hasan M, Dobbs N, Khan S, White MA, Wakeland EK, Li QZ, et al. Cutting edge: inhibiting TBK1 by compound II ameliorates autoimmune disease in mice. J Immunol 2015; 195: 4573â4577.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0420">
                     <ce:label>84</ce:label>
                     <sb:reference id="h0420">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Lefranc</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>V.K.</ce:given-name>
                                 <ce:surname>Schulze</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>R.C.</ce:given-name>
                                 <ce:surname>Hillig</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.</ce:given-name>
                                 <ce:surname>Briem</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>F.</ce:given-name>
                                 <ce:surname>Prinz</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>A.</ce:given-name>
                                 <ce:surname>Mengel</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Discovery of BAY-985 a highly selective TBK1/IkkÎµ inhibitor</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Med Chem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>63</sb:volume-nr>
                              </sb:series>
                              <sb:date>2019</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>601</sb:first-page>
                              <sb:last-page>612</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx430">Lefranc J, Schulze VK, Hillig RC, Briem H, Prinz F, Mengel A, et al. Discovery of BAY-985 a highly selective TBK1/IkkÎµ inhibitor. J Med Chem 2019; 63: 601â612.</ce:source-text>
                  </ce:bib-reference>
                  <ce:bib-reference id="b0425">
                     <ce:label>85</ce:label>
                     <sb:reference id="h0425">
                        <sb:contribution langtype="en">
                           <sb:authors>
                              <sb:author>
                                 <ce:given-name>A.P.</ce:given-name>
                                 <ce:surname>Crew</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>K.</ce:given-name>
                                 <ce:surname>Raina</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>H.Q.</ce:given-name>
                                 <ce:surname>Dong</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>Y.M.</ce:given-name>
                                 <ce:surname>Qian</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>J.</ce:given-name>
                                 <ce:surname>Wang</ce:surname>
                              </sb:author>
                              <sb:author>
                                 <ce:given-name>D.</ce:given-name>
                                 <ce:surname>Vigil</ce:surname>
                              </sb:author>
                              <sb:et-al/></sb:et-al>
                           </sb:authors>
                           <sb:title>
                              <sb:maintitle>Identification and characterization of von hippel-lindau-recruiting proteolysis targeting chimeras (PROTACs) of TANK-binding kinase 1</sb:maintitle>
                           </sb:title>
                        </sb:contribution>
                        <sb:host>
                           <sb:issue>
                              <sb:series>
                                 <sb:title>
                                    <sb:maintitle>J Med Chem</sb:maintitle>
                                 </sb:title>
                                 <sb:volume-nr>61</sb:volume-nr>
                              </sb:series>
                              <sb:date>2018</sb:date>
                           </sb:issue>
                           <sb:pages>
                              <sb:first-page>583</sb:first-page>
                              <sb:last-page>598</sb:last-page>
                           </sb:pages>
                        </sb:host>
                     </sb:reference>
                     <ce:source-text id="stx435">Crew AP, Raina K, Dong HQ, Qian YM, Wang J, Vigil D, et al. Identification and characterization of von hippel-lindau-recruiting proteolysis targeting chimeras (PROTACs) of TANK-binding kinase 1. J Med Chem 2018; 61: 583â598.</ce:source-text>
                  </ce:bib-reference>
               </ce:bibliography-sec>
            </ce:bibliography>
         </tail>
      </article>
   </xocs:serial-item></xocs:doc></originaltext></full-text-retrieval-response>